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ABSTRACT 
Cardiovascular disease is the leading cause of human death worldwide. Currently, 
the prevalence of cardiovascular disease and health care costs associated with its onset 
continue to increase in both developed and developing societies. Concordant with the 
need to improve preventative measures is the imperative to develop more effective and 
efficient remedies for incident cardiovascular pathologies. Increased aortic stiffness with 
aging has recently emerged as an early, independent, and consistent physiological 
predictor of cardiovascular disease and represents an attractive target for possible 
therapeutic options. The success of any biomedical strategy in this regard is incumbent 
upon comprehension of biological processes and mechanical properties attributable to 
constituent components within the aortic wall. 
This dissertation tested the hypothesis that aging-induced changes to smooth 
muscle maintenance of biomechanical homeostasis within the aorta lead to undesirable 
increases in stiffness, correlative with increased risk of negative cardiovascular outcomes. 
Conventionally, mechanical studies and models have identified extracellular matrix as the 
primary determinant of changes in stiffness, but new research presented here shows that 
this may not be true. In viable ex vivo preparations of aortic tissue, roughly half of the 
v 
maximal elastic modulus results from alpha-agonist activation of smooth muscle cells. 
Investigation of the biochemical interactions that characterize this effect revealed a link 
between aging and decreased expression of Src, a kinase involved in numerous signaling 
pathways governing cellular growth and survival, as well as defective regulation of focal 
adhesions between the smooth muscle cells and extracellular matrix. 
These findings were integrated into a model of aortic contractility and stiffness 
that establishes an aging-impaired regulatory complex comprising focal adhesions and 
non-muscle actin cytoskeleton in vascular smooth muscle cells. A better understanding of 
the mechanisms underlying this model may motivate the design of potential therapeutics, 
deliverable to previously overlooked target sites within aortic smooth muscle, and 
ultimately novel treatments for aging-induced cardiovascular disease. 
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Chapter 1: Introduction and Background 
 
1.1 Purpose 
Aortic stiffness is an early and independent biomarker of aging-induced 
cardiovascular disease. This dissertation introduces new biological knowledge regarding 
the underlying mechanisms regulating aortic stiffness attributable to vascular smooth 
muscle cells within the vessel wall, as well as how these mechanisms change with aging. 
The findings are presented in a biomechanical context, relative to the contributions of 
other wall components, in order to highlight the importance of vascular smooth muscle as 
a site of biochemical changes correlated with increased stiffness. These observations 
motivated the subsequent investigation of potential therapeutics targeting the cellular 
processes that modulate aortic stiffness. 
 
1.2 Aortic Stiffness as an Emergent Focus of Cardiovascular Research 
1.2.1 Cardiovascular Disease 
Cardiovascular disease (CVD), a designation for the spectrum of dysfunction and 
disorders that affect the heart and blood vessels, is the leading cause of death worldwide 
and becoming increasingly prevalent in underdeveloped and developing countries 
(Mendis et al. 2011). Mortality rates have decreased in highly-developed countries, but it 
has been shown that currently available preventative measures are less effective in adults 
than in young people (McGill Jr. et al. 2008). Risk factors are myriad and include age, 
chronic conditions, family history, diet, and lifestyle. Statistical accounts and projections 
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of incidence, death, and health care costs are stark. Presently, CVD is responsible for 
more than one out of every three deaths in the United States. This figure may increase to 
~44% between 2014 and 2030, while more than doubling the direct medical costs over 
this timespan, before accounting for additional indirect costs due to lost productivity 
(Mozaffarian et al. 2015). Thus, this pervasive public health issue presents an imperative 
to improve preventative care for CVD. 
 
1.2.2 Pulse Wave Velocity: The Clinical Standard for Aortic Stiffness 
In recent years, arterial stiffness has entered the spotlight as a specific and 
independent risk factor that may wield potent prognosticative power. Arterial stiffness is 
known to precede conditions associated with CVD such as hypertension and 
atherosclerosis, which are subsequently linked to causes of mortality such as heart failure, 
stroke, and kidney disease (Dustan et al. 1996, Guerin et al. 2001, Kaess et al. 2012, Ross 
1999, Ross 1993). Consequently, arterial stiffness is gaining traction as a critically 
important concept in combating the human and societal costs of CVD. 
In broad terms, arterial stiffness is the resistance of arteries to deformation in 
response to an applied force. Pulse wave velocity (PWV) is a non-invasive measurement 
of hemodynamic properties that is readily obtainable in vivo and highly reproducible 
(Wilkinson et al. 1998). Mathematically, it represents the velocity of a pulse resulting 
from systolic ejection of blood from the left ventricle, characterized by the ratio of 
distance ΔL between two measuring sites of a pulse wave to the time delay Δt between 
observations of the wave at each site, or ΔL/Δt. Classically, PWV is interpretable as an 
3 
approximation of arterial stiffness by its relation to the elastic modulus of a blood vessel 
as described by the Moens-Korteweg equation (Korteweg 1878): 
 
PWV =  √𝐸ℎ 2𝜌𝑎⁄       Equation 1 
 
where E is the Young’s modulus or material stiffness, h and a are the thickness and 
radius of the vessel wall respectively, and ρ is blood density. Most commonly, PWV is 
measured via ultrasound between the carotid and femoral arteries (Mitchell 2009). 
Large arteries are better determinants of age-related cardiovascular risk, given 
that they are compositionally different from peripheral arteries and change much more 
drastically with aging (Greenwald 2007, Trachet et al. 2015). The value of PWV as a 
representation of aortic stiffness and an early, independent, and reproducible biomarker 
of CVD is well-documented and thematically recurrent in medical and scientific 
literature. Increased PWV has been observed in a broad spectrum of individuals ranging 
from aged individuals with no other apparent disease (Mattace-Raso et al. 2006, Willum-
Hansen et al. 2006) to those with disorders such as hypertension (Laurent et al. 2001), 
diabetes mellitus (Cruickshank et al. 2002), emphysema (McAllister et al. 2007), and 
end-stage renal failure (Blacher et al. 1999). Elevated PWV in the large vessels leads to 
increased transmission of high pressures to small vessels downstream and is thought to 
cause remodeling of the microcirculation and subsequent adverse effects on end organ 
function. Recently, increases in PWV have been shown both to precede and be 
augmented by hypertension (Weisbrod et al. 2013). Collectively, these studies in humans 
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indicate that increased aortic PWV is prognostic, and may be causative, of cardiovascular 
disease and mortality (Ben-Shlomo et al. 2013, Laurent and Boutouyrie 2007, Mitchell et 
al. 2007). 
Other indirect, non-invasive measurements of arterial stiffness, such as 
augmentation index (AIx), focus on the analysis of pressure waves emanating from the 
heart during pulsation and how they relate to heart rate and mean arterial pressure 
(Wilkinson et al. 2000). While viable, these methods do not necessarily offer a simpler, 
more accurate, or more useful representation of stiffness (Vyas et al. 2007). Currently, 
PWV remains the clinical “gold standard” in this regard. 
 
1.3 The Importance of Ex Vivo Material Stiffness 
1.3.1 Biomechanical Limitations of Pulse Wave Velocity 
Given the ease with which it can be obtained, PWV is a useful estimate of aortic 
stiffness. Unfortunately, it may also be an oversimplification of actual vessel mechanics 
which are much more complex. The applicability of the Moens-Korteweg relation 
between PWV and the mathematical definition of aortic stiffness is dependent on the 
assumption that the wall is isotropic and homogeneous and undergoes small 
isovolumetric changes in response to pulse pressure wave propagation. It has been shown 
in previous studies that this assumption does not hold (Clark and Glagov 1985, Gosling 
and Budge 2003). Furthermore, PWV is also sensitive to changes in heart rate and blood 
pressure (Mitchell et al. 1997). Therefore, this equation is inaccurate beyond conditions 
of specific pressures and wall geometry. 
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1.3.2 Functional Versus Material Stiffness 
In standard terminology derived from past studies, there are two common 
definitions of stiffness as measured from the response of vessels to specific applied 
pressures ex vivo. Functional stiffness, also known alternatively as the pressure-strain 
elastic modulus (Ep) or Peterson’s modulus, refers to the ratio of the change in pressure 
to the change in strain, which itself is a normalized, dimensionless measurement of the 
change in vessel diameter relative to its value at some reference, such as systole or 
diastole. Material stiffness, also known as Young’s modulus (E)—equivalent to the 
elastic modulus in the Moens-Korteweg equation—is functional stiffness normalized 
across the thickness of the arterial wall. Young’s modulus is the most independent 
representation of the intrinsic property of a material to resist deformation when a force is 
applied to it (Gamble et al. 1994, Greenwald 2007, O'Rourke 1990). 
It is more accurate to categorize PWV as representative of functional stiffness. 
Functional stiffness is derived from material stiffness, but the opposite is not true. This is 
a subtle difference rarely appreciated in the literature. Frequently, the type of stiffness 
presented in studies is not explicitly clarified as either material or functional stiffness. 
Precise evaluation of arterial wall thickness is also difficult, which may account for why 
Young’s modulus is not as thoroughly pervasive in reports of stiffness throughout the 
literature as it should be. Again, different terms used in reference to biomechanical 
properties of aorta may present significant difficulties, compounded by the prevalence of 
terms reciprocal to stiffness such as “compliance” and “distensibility,” which are 
sometimes used interchangeably among studies in the context of independence from 
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vessel geometry. Even when attempting to normalize for geometry, one must tread with 
caution. Dimensional calculations based upon cross-sectional area, blood vessel diameter, 
or blood volume may all be equally valid but also mutually unintelligible without proper 
definitional context. The most concise discussion of this complicated canvas is provided 
by Bank and Kaiser, who cite conflicting results attributable to imprecise terminology 
and additionally summarize their own study showing that changes to PWV in brachial 
arteries, in response to smooth muscle relaxation, are not necessarily predictive of any 
corresponding change in material stiffness (Bank and Kaiser 1998). 
 
1.3.3 Building a Contextual Bridge 
Assessment of aortic stiffness exists on multiple scale levels. Macroscale 
techniques such as PWV relate to the hemodynamics of pulsatile blood flow; they are 
applicable in a clinical setting and more easily interpretable. Inversely, microscale 
techniques are difficult to employ non-invasively, but better elucidate the mechanisms 
causative of changes in the physical properties of blood vessels (Kohn et al. 2015). 
Despite the advantages in accessibility to defining aortic stiffness by way of a 
representative measurement such as PWV, there is a need for improvement in the 
contextualization of the biological activity underlying the dynamics of stiffness. While 
PWV is an easily demonstrable and a clinically valuable measure of functional stiffness, 
there is also a strong impetus to evaluate material stiffness directly to explain how 
different components of the aortic wall, a highly complex and layered network of 
interconnected cellular and extracellular elements, contribute to altered or defective 
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mechanisms in disease models. This is most conveniently and commonly done ex vivo by 
subjecting aortic tissue to mechanical stretch. 
Therefore, one primary objective of this dissertation is to establish a logical 
connection between ex vivo material stiffness measurements and observable regulatory 
effects of stiffness by constituent components of the aortic wall. Naturally, the ability to 
do so rests upon a comprehensive biological understanding of these components. 
 
1.4 Aortic Vascular Tissue 
1.4.1 General Wall Structure 
The aortic wall is a stratified composite of smooth muscle cells (SMCs) and 
extracellular matrix, as well as connective components such as cadherins and integrins 
linking them; each layer is different in its specific proportionality of these constituents. 
Moving outward through the vessel surrounding the arterial lumen, the major layers of 
the arterial wall are the intima, the media, and the adventitia. The intima includes 
endothelial cells that are in direct contact with blood flow. Elastin, organized into a three-
dimensional lamellar network that contains collagen bundles between layers, is prevalent 
in the media, which also contains most of the SMCs (Matsumoto and Nagayama 2011, 
Wagenseil and Mecham 2009). Outside the external elastic lamina lies the adventitia, 
where fibroblasts produce most of the aortic wall’s collagen (Wagenseil and Mecham 
2009). A schematic of the aortic wall appears in Figure 1.1. 
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Figure 1.1. Idealized architecture of a healthy human artery (Tsamis et al. 2013). 
Arterial structure consists of an inner layer (intima, I), middle layer (media, M), and outer 
layer (adventitia, A). The intima is composed mainly of a single layer of endothelial cells. 
The media contains smooth muscle cells, a network of elastin and collagen fibrils, and 
elastin lamellae. The adventitia is primarily composed of thick bundles of collagen fibers. 
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1.4.2 Smooth Muscle Cells 
Vascular smooth muscle cells (VSMCs) are involved in contractile and synthetic 
processes and are capable of exhibiting different phenotypes corresponding to these 
functions. By altering the diameter of the arterial lumen during contraction and 
relaxation, contractile VSMCs, which make up the majority of vasculature, maintain 
homeostatic blood pressure. Synthetic VSMCs facilitate long-term adaptive measures via 
synthesis of ECM components and instigation of cell proliferation and migration during 
vessel remodeling due to injury or other environmental perturbations. There are marked 
differences between contractile and synthetic SMCs. Contractile SMCs are spindle-
shaped and relatively non-motile, while synthetic SMCs are shorter, possess high 
numbers of organelles involved in protein synthesis, and exhibit migratory behavior 
(Rensen et al. 2007). Consistent with these categorizations is the fact that when cultured, 
VSMCs change in phenotype from contractile to synthetic (Campbell and Campbell 
1995). 
The structure of VSMCs is a lattice consisting of the non-muscle cytoskeleton and 
a contractile apparatus (see Figure 1.2). The cytoskeleton has as its major components 
intermediate filaments, accounting for shape maintenance, and actin filaments, which 
interact with cytoplasmic dense bodies. Traditionally, the primary link from the SMC 
cytoskeleton to the contractile apparatus is in the form of these dense bodies, which 
contain α-actinin and bind to oppositely polarized actin filaments of the contractile 
apparatus (Draeger et al. 1990, Small and Gimona 1998). 
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Figure 1.2. The smooth muscle cell model of cytoskeleton (Csk). Shown are the non-
muscle actin filaments (n-m. act) that interact with dense bodies (db), muscle actin 
filaments (m. act) and myosin (my) of the contractile apparatus, intermediate filaments 
(If), and dense plaques or cortical focal adhesions (dpl) (Small and Gimona 1998). 
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As in all muscle and some non-muscle cells, the actomyosin cross bridge cycle is 
the fundamental mechanism of contractility in SMCs. Myosin filaments activated by 
contractile stimuli are able to “row” along actin filaments through ATPase activity and 
generate tension, shortening the cell as a result. Increases in intracellular calcium levels 
activate myosin light-chain kinase (MLCK), which regulates the cross bridge cycle via 
phosphorylation (Ogut and Brozovich 2003, Uehata et al. 1997). 
Studies have shown that actin polymerization is also a predicate for smooth 
muscle contraction; the contraction of SMCs is associated with a transition in a small 
proportion of total actin in the cell from globular, or monomeric, to filamentous, and 
inhibition of actin polymerization results in a decrease in contractility (Cipolla and Osol 
2002, Flavahan et al. 2005, Kim et al. 2010, Srinivasan et al. 2008, Zhang et al. 2005). 
This same inhibition, however, has been found not to have an effect on either intracellular 
calcium levels or myosin light-chain phosphorylation (Gunst and Zhang 2008, Shaw et al. 
2003). While actin filaments constitute up to 20% of all protein content, only a subset 
collectively known as contractile actin is involved in interacting with myosin. Actin-
binding proteins, such as caldesmon, serve as regulators of the accessibility of actin to 
myosin. These proteins are themselves regulated by upstream signaling molecules such as 
extracellular signal-regulated kinases (ERK1/2) (Kim et al. 2008, Yamin and Morgan 
2012). Thus, myosin activity and actin availability are two major factors that affect cell 
contractility. A third potential influence on contractility in VSMCs is actin cytoskeletal 
remodeling, confirmed in recent studies by our group (Kim et al. 2010, Saphirstein et al. 
2015). 
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Actin filaments also interact with longitudinal arrays on the membrane skeletons 
of SMCs known as dense plaques or focal adhesions, sites of mechanotransduction 
(Gerthoffer and Gunst 2001, Li et al. 2009, Small and Gimona 1998). 
 
1.4.3 Focal Adhesions 
Mechanotransduction, the process by which biochemical responses manifest from 
mechanical signals, is mediated in vasculature by virtually all major components in the 
vessel walls, including cytoskeletal structures and transmembrane receptors in the 
VSMCs, ECM components such as elastin and collagen, cell-cell adhesions, and cell-
matrix adhesions (Ingber 2006, Ingber 2003). 
Focal adhesions (FAs) are macromolecular complexes that belong to the latter 
category. They physically connect the cytoskeleton to ECM, generally via heterodimeric 
integrins, and also serve as sites of transmission for both regulatory signals and 
mechanical activity, capable of recognizing both physical and chemical stimuli in the 
cellular environment (Geiger et al. 2009). More than 150 proteins have been reported to 
have an association with FAs; organization and interaction among these proteins allows 
for diversity in structure and function (Zaidel-Bar et al. 2007, Zamir and Geiger 2001). 
Focal adhesion activity is traceable as part of a growth and maturation cycle in the form 
of a positive feedback loop, dependent upon the development of tension to grow, and 
prone to rapid dissociation upon relaxation (Wolfenson et al. 2009). 
FAs enable two-way mechanical signaling, either from external forces (outside-
in) or internal tension generated from actomyosin contraction (inside-out). Recent studies 
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have shown that actomyosin-generated forces modulate molecular kinetics of FAs 
(Wolfenson et al. 2011). More generally, FA size, quantity, and organization can be 
controlled by cell shape through changes in cell contractility. On the other hand, while 
ECM binding is necessary for FA formation, ECM by itself is insufficient for the 
promotion of FA assembly, although external forces are still capable of inducing FA 
development (Chen et al. 2003, Galbraith et al. 2002). In concert with studies that 
demonstrate an ability of cell shape to regulate contractile force, these findings show that 
regulation of FA assembly obeys an inside-out mechanism (Chen et al. 2003, Tan et al. 
2002, Wang et al. 2002). This may have further implications regarding an intrinsic link 
between VSMCs and FAs in their contributions to arterial stiffness. 
While FA integrins are not catalytic—any signaling caused by interactions with 
ECM must be transduced into cells through integrin-associated proteins (Hynes 2002, 
Juliano 2002, Schwartz 2001)—tyrosine phosphorylation of cytoskeletal and signaling 
proteins is one of many intracellular signaling events that result from integrin clustering. 
Focal adhesion kinase (FAK) is a tyrosine kinase that is localized to integrin clusters. 
FAK is recruited by the focal adhesion targeting region, a C-terminal domain with 
binding sites for integrin-associated proteins such as talin and paxillin (Rembold et al. 
2007). These proteins may regulate arterial contraction based on previous research 
demonstrating this effect in in airway smooth muscle (Schlaepfer et al. 2004, Wang et al. 
1996). 
The activated catalytic domain of FAK auto-phosphorylates Y397, facilitating the 
binding of Src-family kinases to the motif surrounding Y397. This formation of a FAK-
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Src complex increases Src kinase activity, which in turn mediates additional 
phosphorylation of FAK within an activation loop of its kinase domain, located at Y576-
Y577, as well as C-terminal domain residues Y861 and Y925. The net result is maximal 
FAK-associated activity and multiple intracellular signaling cascades, including the 
promotion of adaptor proteins such as paxillin, cytoskeletal proteins such as α-actinin, 
and GTPases such as Ras and Rho, the latter of which is a family of cellular molecular 
switches that regulate the formation and disassembly of actin-based cytoskeletal 
structures (Izaguirre et al. 2001, Kuo et al. 2011, Martinez-Lemus et al. 2009, Mitra et al. 
2005, Schlaepfer et al. 1999). Therefore, the FAK-Src complex is a target of interest in 
ascertaining the role that focal adhesion growth and regulation may play in arterial 
stiffening. 
There have not been many studies conducted upon FAs associated with non-
migrating contractile SMCs, which account for the vast majority of what is observed in 
vivo in the vasculature. Given their importance as a conduit between the VSMCs and 
ECM of the arterial wall, FAs must be taken into account in the development of any 
comprehensive model of wall mechanics. A schematic summary of VSMC-mediated 
regulatory pathways of aortic stiffness related to FAs is shown in Figure 1.3.  
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Figure 1.3. Regulation of smooth muscle contractility (Kim et al. 2008). (A) 
Demonstrated and putative signaling pathways that regulate myosin activity, actin 
availability, and cytoskeletal remodeling all contribute to contractility in vascular smooth 
muscle. (B) Focal adhesion complex linker (green) and signaling (orange) proteins 
promote cytoskeletal remodeling in response to mechanical and/or contractile stimuli. 
A 
B 
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1.4.4 Extracellular Matrix 
In healthy arteries, the tunica media is the most mechanically significant layer of 
the wall. A helical, lamellar helical network of elastin fibers in the media, approximately 
circumferential in orientation, transfers stress throughout the wall (Holzapfel et al. 2000). 
Wavy Type I collagen fibers define a clear plane of separation between successive layers 
of this elastin network (Clark and Glagov 1985). These collagen bundles are of indefinite 
arrangement at low stress. Only with an increase in pressure and stretch does the collagen 
also align itself circumferentially (Dobrin 1978, Roach and Burton 1957, Wolinsky and 
Glagov 1964). Therefore, at low pressures, the load is taken on almost entirely by elastin, 
while the gradually unfolding collagen fibers bear increasingly more tension as the vessel 
continues to be stretched. It is well-documented that arterial stiffness is non-linear; at 
high pressures, it becomes much more difficult to distend the vessel, owing to the 
increase in stiffness in the form of collagen recruitment. This behavior is critical for 
protection against aneurysms and rupture (Shadwick 1999). Recent studies indicate that 
the adventitial layer, in which ECM material is predominantly collagen, may also bear a 
significant contribution to stiffness (Greenwald 2007, Schulze-Bauer et al. 2002, Xie et 
al. 1995). This framework buoys a long-held notion among biomechanical researchers 
that tissue stiffness can be largely attributed to ECM (Wagenseil and Mecham 2009). 
 
17 
1.5 Targeting Aging-Induced Increases in Aortic Stiffness 
1.5.1 Changes with Aging in Aortic Structure and Function 
As of 2015, it is estimated that more than 85 million people in the United States 
have at least one type of CVD; more than half of these (43–44 million) are at least 60 
years of age. As a correlative factor with increased aortic stiffness and subsequently 
higher risk of CVD, senescence is the ideal context in which to develop potential 
therapeutics. 
Many physical and biochemical changes occur within the aortic wall with aging. 
In broad terms, these have ramifications on blood flow, pressure, and burden on the heart 
(Lakatta 2003). As illustrated in Figure 1.4, resulting positive feedback that leads to 
further remodeling culminate in functional changes at the cellular level that may play a 
role in further aortic stiffening (Greenwald 2007). Therefore, any attempt to canonize a 
model of increased aortic stiffness with aging—and related conditions such as 
hypertension and atherosclerosis—must incorporate a comprehensive understanding of 
these effects on structure and function in different wall components. Otherwise, clinical 
treatments that aim to reduce aortic stiffness may be poorly directed and lacking in 
specificity. 
Changes with aging in aortic ECM are perhaps the most readily observable. There 
is general agreement that, with aging, the ratio of collagen to elastin in wall tissue 
increases, and that both the density and integrity of the fatigued and progressively 
disorganized elastin lamellae decrease, although the absolute amounts of both matrix 
proteins decrease (Cattell et al. 1996, Greenwald 2007). Underlying causes of these  
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Figure 1.4. Interrelationships between vessel composition, structure, elasticity, 
geometry, impedance to blood flow, and cardiac work (Greenwald 2007). An 
increased burden on the major conduits of the circulatory system results in an increase in 
vessel stiffness that propagates to peripheral vasculature, which in turn triggers further 
stiffness increases in a positive feedback mechanism. 
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changes in the ECM include cross-linking of collagen and possibly also elastin, induced 
by accumulation of advanced glycation end-products (AGEs) resulting from slow and 
chemically irreversible rearrangements produced by glycation and oxidizing reactions 
within protein molecules. This translates to an increase in aortic material stiffness 
(Aronson 2003, Konova et al. 2004, Winlove et al. 1996). 
Meanwhile, VSMCs are capable of switching their phenotype from contractile to 
synthetic with aging, causing fundamental changes in cellular function. As the SMCs 
migrate and proliferate, the intima thickens and the aorta undergoes increases in lumen 
diameter and wall thickness (Avolio et al. 2011, Glagov et al. 1993, Intengan and 
Schiffrin 2000). The cells themselves are also stiffer (Qiu et al. 2010). These effects give 
rise to defects in the mechanotransductive processes of VSMCs, which are commonly 
observed in a wide range of diseases (Ingber 2006, Ingber 2003). 
Finally, the endothelium has also become increasingly visible in this regard, as it 
is responsible for widespread effects on cellular and extracellular processes throughout 
the aortic wall and especially those linked to VSM function. Nitric oxide (NO) produced 
by endothelial cells induces vasodilation and relaxation in VSM (Russell and Watts 
2000). NO bioavailability is reduced with aging, which attenuates this benefit, increasing 
the stiffness of VSM as a result. This downstream effect may characterize yet another 
powerful positive feedback loop where the increased stiffness leads to further reduction 
of NO (Avolio et al. 2011, Cannon III 1998). 
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1.5.2 The Case for Studying Vascular Smooth Muscle 
While all major biological components of the aortic wall play integral roles in the 
upkeep of normal cardiovascular function, it is clear from a brief outline of aging-induced 
effects on the aorta that vascular smooth muscle represents a common thread involved in 
all major structural and functional changes that deserves to be the focus of ongoing 
investigation. 
The biological mechanisms underlying the contributions of vascular smooth 
muscle cells to the determination and regulation of aortic stiffness, and the effects of 
aging on these mechanisms, are not well understood. While numerous classical and 
recent studies of vascular mechanics attribute the majority of vessel wall stiffness largely 
to the ECM (Berry et al. 1975, Fleenor et al. 2010, Fleenor et al. 2012, Greenwald 2007, 
Wagenseil and Mecham 2009, Wolinsky and Glagov 1964), which is prominently 
featured in quantitative models (Holzapfel and Ogden 2010, Humphrey and Holzapfel 
2011, Valentin et al. 2011, Wagenseil and Mecham 2012, Zulliger and Stergiopulos 
2007), there are also those that indicate that vascular smooth muscle activation produces 
non-negligible increases in stiffness (Bank et al. 1996, Barra et al. 1993, Gao et al. 2014). 
The analysis of biomechanics in vascular smooth muscle can provide a 
quantitative description of hemodynamic phenomena such as blood flow and pulsatile 
wave propagation (Murphy 1988). Understanding changes to the mechanical properties 
of blood vessels is vital to assembling a broader grasp of how aging and other forms of 
disease affect cardiovascular physiology. By employing a quantitative approach to parse 
contributions to aortic stiffness from constituent components of the aortic wall, one may 
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identify the corresponding biological mechanisms that most significantly determine and 
regulate aortic stiffness and study how they change with aging. A rigorous regimen of ex 
vivo biomechanical and biochemical analyses to probe and understand these mechanisms 
in vascular smooth muscle may facilitate the design of potential therapeutics deliverable 
to previously overlooked targeting sites, leading to novel treatments for the onset and 
progression of cardiovascular disease with aging. 
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Chapter 2: Materials and Methods 
 
2.1 Disclosure 
Text and figures in the following sections in this chapter were modified from 
(Gao et al. 2014): 2.2, 2.4.1, 2.4.2, 2.5.1, 2.5.2, 2.5.3, 2.5.4, and 2.6. 
 
2.2 Ethical Approval 
 All procedures were performed in accordance with protocols approved by the 
Boston University Institutional Animal Care and Use Committee (Permit Number: 
A3316-01). Animals (C57BL/6J mice) were maintained according to guidelines in the 
NIH Guide for the Care and Use of Laboratory Animals. Acquisition and usage of 
animals were in compliance with federal, state, and local laws. Euthanasia with isoflurane 
inhalation preceded expedient removal of tissue. 
 
2.3 Mouse Models of Aortic Stiffness 
Most of the research outlined here is based upon aorta samples from the C57BL/6, 
or Black 6, mouse model. Vasculature in rodent models such as Black 6 do not resemble 
humans as closely as that in ferrets, for example (Cavagna et al. 2000). Nevertheless, 
Black 6 offers distinct advantages due to its widely and robustly understood physiology 
and genetics, as well as its accessibility. Compiled through extensive studies, the aging 
curve in Figure 2.1 provides age equivalency between C57BL/6J mice and humans, 
enabling proper contextualization of vascular aging studies performed in these animals 
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Figure 2.1. Representative age ranges for mature life history stages in C57BL/6J 
mice. Comparative development rates between mice and humans are as follows: 150 
times faster between birth and 1 month, 45 times faster between 1–6 months, 25 times 
faster at > 6 months (Flurkey et al. 2007). 
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Aortas were excised from euthanized male C57BL/6J mice according to protocols 
approved by the Institutional Care and Use Committee (IACUC) of Boston University. 
Studies were performed on “young” and “old” mouse populations at 3 and 29 months of 
age respectively, with variability of ± 1 month. Animals were provided by Jackson Labs, 
with support from the National Institute of Aging. 
 
2.4 Aortic Tissue Sampling 
2.4.1 Preparation of Tissue 
Harvested aortas were immediately placed in a physiological salt solution (Krebs 
PSS: 120 mM NaCl, 5.9 mM KCl, 11.5 mM dextrose, 25 mM NaHCO3, 1.2 mM 
NaH2PO4, 1.2 mM MgCl2, 2.5 mM CaCl2; pH = 7.4) equilibrated with 95%-5% O2-CO2. 
Loose perivascular fat was removed from aortic samples. Segments of 4–5 mm in axial 
length (unloaded) were isolated from the proximal end of the descending thoracic aorta. 
There was no significant difference in axial length from cut segments with age. 
 
2.4.2 Measurements of Aortic Geometry 
Axial length and outer diameter of samples were measured under a light 
microscope (4x) during aortic dissection of unloaded segments in PSS. Small rings 
adjacent to both ends (proximal and distal) of the thoracic aorta ring to be studied were 
incubated for 30 minutes in nuclear stain (NucBlue from Life Technologies). After the 
incubation period, individual rings were imaged with fluorescence microscopy (20x) for 
auto-fluorescence of medial elastin fibers and the NucBlue stain via NIS-Elements 
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software (Nikon Instruments); Figure 2.2 features an image of a sample ring. For each 
ring, 15–20 measurements were taken and averaged to obtain a single value for the 
medial thickness. These measurements of both proximal and distal thoracic aortic rings 
were then averaged to obtain a single representative unloaded wall thickness 
measurement for the thoracic aorta segment to be studied. 
 
2.5 Evaluation of Aortic Tissue Stiffness Ex Vivo 
2.5.1 Uniaxial Stretching Apparatus and Normalization of Force Measurements 
Thoracic aorta segments were suspended in an organ bath (volume: 60 mL), 
submerged in oxygenated Krebs PSS warmed to 37ºC by a thermostat-controlled water 
bath and circulation system to maintain viability and threaded with triangular wire clasps. 
This allows the segments to be stretched uniaxially in a way that simulates 
circumferential distension. Results from all of Chapter 4, as well as Chapter 3.4.5, were 
obtained using wire of 0.01 inches in diameter. All other results were obtained using wire 
of 0.005 inches in diameter. 
Stretch was monitored by the Model 300C Dual-Mode Lever Arm System by 
Aurora Scientific, Inc. (Aurora Scientific, Ontario, Canada) and performed by using an 
electronic input to the lever arm motor via a function generator. Chart software (AD 
Instruments) was used for data acquisition from the system. The extent of stretch 
performed to obtain a steady-state force response, known as the operating length and 
specific to each sample, was established as circumferential strain ε, a percentage of outer 
aortic diameter of that sample in the unloaded state.  
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Figure 2.2. Fluorescence microscopy of a young mouse aortic wall cross-section. 
Wall thickness of an aortic sample is measured from fluorescence of medial elastin fibers 
(green) and nuclear stain for smooth muscle cells (blue). 
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The lever arm also served as a force transducer, allowing for measurements of a 
steady-state force F, the equilibrated response after stretching to the operating length. 
Dividing force by the axial length l of the tissue normalizes it to wall tension. 
Circumferential stress σ was obtained by normalizing F to cross-sectional area A of 
unloaded tissue: σ = F/A and A = 2hl, where h is the wall thickness and l is the axial 
length. 
 
2.5.2 Quasi-Static Stress-Strain Curves 
Using the same stretching apparatus, stress-strain curves were obtained from force 
responses to slow, high-amplitude ramp stretches applied from the unloaded state, or 
slack length. The strain rate applied to aortic samples was 20% per second, up to either a 
maximum of 400% or the point of tissue yield and rupture. The force response 
corresponding to the loading curve was normalized to stress. Stiffness values for specific 
strains were obtained by plotting stress against strain and calculating the local slope, i.e., 
the elastic modulus, around specific strain levels. Tissues were maintained in calcium-
free PSS (120 mM NaCl, 5.9 mM KCl, 11.5 mM dextrose, 25 mM NaHCO3, 1.2 mM 
NaH2PO4, 1.2 mM MgCl2, 2 mM EGTA; pH = 7.4) to isolate passive mechanical 
properties of the aortic wall attributable to extracellular matrix and minimize 
contributions from vascular smooth muscle cells. 
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2.5.3 High-Frequency Low-Amplitude Sinusoidal Perturbations 
Ex vivo aortic stiffness is defined in this study as the material stiffness of aortic 
tissue, equivalent to the elastic modulus derived from directly measurable circumferential 
force responses to small-length oscillations (Kawai and Brandt 1980). High-frequency 
(40 Hz), low-amplitude (+1% of slack diameter superimposed upon optimal length) 
sinusoidal strain (HFLA) was applied persistently to obtain a time course of force-
response data. Based on previous studies and confirmed experimentally here, these 
parameters resulted in negligible phase lag of the force response or breakage of 
actomyosin cross bridges in the tissue (Brozovich and Morgan 1989). Solution changes 
were conducted without disturbance to the ongoing movement of the lever arm or the 
force trace as monitored via software. 
As shown in Figure 2.3, oscillatory sinusoidal input produced a force response 
from which the change in stress is calculated as the amplitude of the force output 
waveform (ΔF) normalized to cross-sectional area A. Stiffness is defined as this change 
in stress divided by the change in strain (1%, ΔL) imposed atop the strain of the operating 
length (L). This strain was applied to equilibrated tissue at least 30 minutes after stretch 
to L. Effectively, the HFLA protocol produces a local stress-strain relationship in the 
neighborhood of the operating length L; the stiffness is the elastic modulus as calculated 
from this response. 
 
29 
 
 
Figure 2.3. Ex vivo steady-state stiffness methods. (A) Schematic of lever arm for 
stiffness measurements; steady-state force response measured from stretching the tissue 
sample (shown here with typical unloaded ex vivo geometry) is that which is experienced 
in the circumferential direction at the center of the axial cross-section (arrow). (B) 
Representative force trace with sample inset of electronic recordings for high-frequency 
low-amplitude (HFLA) oscillatory stretch; sinusoidal length input (ΔL) and force output 
(ΔF) were used to calculate stiffness at optimal length L. Stiffness E is the ratio of change 
in stress (Δσ, equivalent to ΔF normalized to cross-sectional area A), to change in strain 
experienced by tissue (Δε). 
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2.5.4 Confirmation of Vascular Smooth Muscle Viability 
Prior to all steady-state force measurements made using the lever arm length 
controller, I used 51mM KCl PSS (75 mM NaCl, 51 mM KCl, 11.5 mM dextrose, 25 mM 
NaHCO3, 1.2 mM NaH2PO4, 5.35 mM MgCl2, 2.5 mM CaCl2; pH = 7.4) to confirm 
VSMC viability in all aortic samples. This solution depolarizes smooth muscle cells and 
opens voltage-gated calcium channels, increasing intracellular calcium levels and 
inducing muscle contraction. A stimulation period of 15 minutes enabled samples to 
approach contractile steady-state. After confirming VSMC viability, I washed out the 
KCl with Krebs PSS and allowed samples an equilibration period of 30 minutes to return 
to an inactivated baseline.  
To maximally activate VSMCs in these samples, I then performed a two-step 
treatment. First, I added 10 μM alpha agonist phenylephrine (PE), which has previously 
been shown to increase contractility by both actin- and myosin-mediated mechanisms 
(Yamin and Morgan 2012) maximally at the noted concentration (Russell and Watts 
2000). Equilibration occurred 15 minutes after addition of PE. Second, after 
equilibration, I followed with the addition of 300 μM L-NG-nitroarginine methyl ester 
(L-NAME), a cell-permeable precursor of nitroarginine that inhibits nitric oxide synthase 
(NOS) (Barton et al. 1998, Rees et al. 1990). Nitric oxide, a product of the intimal 
endothelial monolayer in the mouse arterial wall, alters aortic smooth muscle tone and 
would be expected to alter stiffness. Equilibration was reached 20 minutes after addition 
of L-NAME. 
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2.6 Biochemical Analysis 
Screening with phosphotyrosine immunoblots as an indicator of focal adhesion 
signaling in quick-frozen young and old mouse aorta homogenates was performed with 
the technical help of Cynthia Gallant and Qian Qian Lin. Tissues were quick-frozen in an 
acetone/dry ice slurry containing 10% trichloroacetic acid (TCA) & 10 mM dithiothreitol 
(DTT), homogenized and processed at 4ºC as described previously by our group 
(Marganski et al. 2005). The homogenization buffer, designed to preserve native 
phosphoprotein levels, consisted of 20 mM MOPS, 4% SDS, 10% glycerol, 10 mM DTT, 
20 mM β-glycerophosphate, 5.5 μM leupeptin, 5.5 μM pepstatin, 20 KIU aprotinin, 2 
mM Na3VO4, 1 mM NaF, 100 μM ZnCl2,20 μM AEBSF, and 5 mM EGTA. 
Densitometric analysis of immunoblots was performed using Odyssey Infrared Imaging 
System (LI-COR Biosciences, Lincoln, NE). Tyrosine phosphorylation densitometry was 
normalized to that of alpha-tubulin densitometry. Tyrosine phosphorylation was 
examined after 15 minutes exposure of the vascular tissue to PE. At this time point, 
VSMC activation has reached steady-state values, corresponding to the maximally 
effective dosage of 10 µM (Russell and Watts 2000). 
 
2.7 Cell-Permeable Decoy Peptides 
2.7.1 Design and Synthesis 
A preliminary investigation of possible synthetic therapeutic treatments for 
increased aortic stiffness regulated by vascular smooth muscle, as detailed in this thesis, 
sought to determine the potential of two cell-permeable peptides (CPP) that competitively 
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inhibit binding sites relevant to regulatory processes for focal adhesion protein-protein 
interactions as well as actin polymerization within aortic vascular smooth muscle cells. 
CPP sequences were designed by Robert Saphirstein, former member of the Morgan 
group at Sargent College and Dr. Paul Leavis of Tufts University with an Applied 
Biosystems model 433A peptide synthesizer by solid-state peptide synthesis using 
fluorenylmethoxycarbonyl chemistry (Kim et al. 2008). 
Peptides were acetylated at their N-termini and a TAT (transactivator of 
transcription) protein transduction domain with the 14-amino-acid sequence 
GSGYGRKKRRQRRR was coupled at the C-termini in order to mediate transfer across 
the cell membrane (Heitz et al. 2009, Marganski et al. 2005). AHX (1-aminohexanoic 
acid), a six-carbon bridge molecule, was used to attach fluorescent tags (FITC or 
rhodamine) enabling visual confirmation of permeation without adverse effects on 
stability. The C-terminus of the AHX is attached to the first lysine in the TAT sequence, 
while the fluorophore is attached to the N-terminus. The study presented in this 
dissertation focuses on two CPPs in active and inactive/scrambled-sequence (-X) forms 
as presented in the Table: TLN-VBS and N-WASP-CA. Mass spectrometry confirmed 
product purity. 
 
2.7.2 Loading Solutions 
From dry powder, loading solutions for CPPs were prepared by dissolution and 
dilution. For each peptide, experimental loading volumes were obtained via diluting 1 
mM stock solutions. Both forms of TLN-VBS were readily soluble in Krebs PSS. To  
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Stock Name Sequence (5'-3') Label 
Mass 
(Da) 
1 
TLN-VBS GRPLLQAAKGLAGAVSELLRSAQPA 
FITC 4762 
2 Rhodamine 4827 
3 None 4116 
4 TLN-VBS-X LLRRSQAALGAAAEVLPQALSGPGK FITC 4762 
5 N-WASP-CA 
TSGIVGALMEVMQKRSKAIHSSDED-
EDEDDEEDFEDDDEWED 
FITC 6907 
6 
N-WASP-CA-X 
DEMLEQEKGDESGIDSGDKDMEEV-
DSWEVEDHSETDIADDE 
Rhodamine 6957 
7 None 6372 
 
Table 1. Cell-permeable decoy peptide (CPP) sequences and stocks. Two CPPs were 
designed for competitive inhibition of binding sites, resulting in disruption of protein-
protein interactions within focal adhesions (TLN-VBS) and processes involved in actin 
polymerization (N-WASP-CA). These CPPs were used in tissue experiments as inhibitors 
of increases in aortic stiffness induced by agonist stimulation of vascular smooth muscle. 
The inactive scrambled forms (-X) of these CPPs were also synthesized to serve as a 
negative control in these tissue stiffness experiments. Several peptide stocks were labeled 
with one of two fluorescent labels (FITC or rhodamine) as denoted; corresponding total 
molecular masses in Daltons are tabulated. 
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dissolve N-WASP-CA, calcium- and magnesium-free Hanks buffered salt solution: 137 
mM NaCl, 5.4 mM KCl, 0.42 mM NaH2PO4 • H2O, 0.44 mM KH2PO4, 4.17 mM 
NaHCO3, 10 mM HEPES, 5.55 mM dextrose; pH = 7.4) was used as the solvent, with 
additional volumes of 1 N NaOH and HCl required to complete dissolution and maintain 
the physiological pH of 7.4. Corresponding to the Table, proportional volume ratios 
were: 89.5% Hanks, 5.5% NaOH, 5% HCl for Stock 5; and 94.5% Hanks, 3% NaOH, 
2.5% HCl for Stocks 6 and 7. Starting with this 1 mM stock solution for each experiment, 
dilution into additional salt solution was performed to obtain 600 µL of loading volume 
with the desired concentrations of peptide: 100 or 250 μM in Krebs (TLN-VBS) or Hanks 
(N-WASP-CA). 
 
2.7.3 Tissue Loading and Unloading 
 Immersing an aortic tissue sample in loading solution is essentially a pre-
treatment procedure; in other words, it must be done before stimulation of the vascular 
smooth muscle. In order to conserve peptide stock, loading was not done in the 60 mL 
organ bath. Instead, one-hundredth of the volume (600 µL) was prepared for use, as 
detailed in the previous section, into the “loading tray,” an apparatus consisting of a 900-
μL well (1.5 cm x 1.5 cm x 0.4 cm) cut into a disk of polydimethylsiloxane (PDMS) gel, 
glued to a double stack of small weigh boats. This loading tray was designed and built 
with the assistance of Robert Saphirstein. 
After dissection of an aortic ring segment, I threaded it with a single triangular 
wire clasp parallel to a piece of straight wire, then transferred the tissue to the loading 
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tray containing the loading solution. Using small surgical pins, I manually stretched the 
tissue to the physiologic strain level corresponding to 80% of the tissue’s unloaded outer 
diameter by pulling the triangular clasp and wire apart to the precise length as measured 
with a light microscope. The tray was then moved to sit atop the organ bath, which was 
filled with distilled water and heated to 37ºC with the circulation system. The dimensions 
of the weigh boat enable its depth to be submerged within the heated water while lying 
balanced atop the organ bath, allowing the liquid in the organ bath to transfer heat to the 
contents of the tray. Finally, the loading solution was bubbled gently with the appropriate 
gas: 95%-5% O2-CO2 for Krebs and O2 for Hanks. Therefore, the peptide is able to 
permeate the vascular smooth muscle cells under the “physiologic” conditions established 
as if the tissue had been mounted inside the organ bath itself. The entire apparatus is 
shown in Figure 2.4. 
I employed a loading period of 30 minutes, after which the apparatus was 
dismantled, and the tissue unmounted from the wires and returned into the dissection 
dish. This completed the peptide loading phase. The regular procedure of mounting the 
tissue onto the standard uniaxial stretching apparatus followed, with the additional step of 
delaying the initial stretch to optimal length by an additional 30 minutes after mounting, 
in order to allow the tissue to recover from the loading procedure and regain its original 
unloaded dimensions. 
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Figure 2.4. Apparatus for peptide loading protocol with aortic tissue. (1) A small 
volume of peptide loading solution (here tagged with rhodamine) is pipetted into a 900-
μL well (1.5 cm x 1.5 cm x 0.4 cm) cut into a disk of polydimethylsiloxane gel that is 
glued to a double stack of weigh boats. (2) Aortic tissue sample is manually stretched 
uniaxially to 80% strain and immersed in the loading solution. (3) The weigh boat rests 
atop an organ bath filled with water warmed to 37º C to simulate body temperature. (4) 
Oxygen line is arranged to provide gentle bubbling into the loading solution. Red scale 
bar: 1 cm. 
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2.8 Reagents 
 Agonist phenylephrine (PE) was obtained from Sigma-Aldrich. PP2 (10 mM in 
solution) was purchased from EMD Biosciences (La Jolla, CA). L-NAME (dry powder) 
was purchased from Cayman Chemical Company (Ann Arbor, MI). NucBlue live cell 
stain was purchased from Life Technologies (Eugene, OR). Antibodies used for 
biochemical analysis were phosphotyrosine (mouse, 1:500) from BD Biosciences (San 
Jose, CA) and alpha-tubulin (rabbit, 1:50,000) from Abcam (Cambridge, MA). 
 
2.9 Statistics 
 Results are reported as mean ± standard error. Unless explicitly stated otherwise 
in figure legends, single statistical comparisons were made with two-tailed Student’s t-
tests, while analysis of variances (ANOVA) and Sidak’s post-hoc test were used for all 
instances of multiple comparisons. Significance tests were performed in GraphPad Prism 
and significance was defined at levels of p < 0.05, 0.01, and 0.001. 
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Chapter 3: Aging Impairs Smooth Muscle Mediated Regulation of Aortic Stiffness 
 
3.1 Disclosure 
Text and figures in the following sections in this chapter were modified from 
(Gao et al. 2014): 3.2, 3.3, 3.4.1, 3.4.2, 3.4.5, 3.4.7, 3.4.8, 3.4.9, 3.5.1, 3.5.2, and 3.5.3 up 
through “Recently, our group has shown that the regulatory role of NMC extends to 
venous stiffness …” 
 
3.2 Summary 
Increased aortic stiffness is an early and independent biomarker of cardiovascular 
disease. Here, I tested the hypothesis that vascular smooth muscle cells (VSMCs) 
contribute significantly to aortic stiffness and investigated the mechanisms involved. The 
relative contributions of VSMCs, focal adhesions (FAs), and extracellular matrix to 
stiffness in mouse aorta preparations at optimal length and with confirmed VSMC 
viability were separated by the use of small molecule inhibitors and activators. Using 
biomechanical methods designed for minimal perturbation of cellular function, I directly 
quantified changes with aging in aortic material stiffness. An alpha adrenoceptor agonist, 
in the presence of L-NAME to remove interference of endothelial nitric oxide, increases 
stiffness by 90–200% from baseline in both young and old mice. Interestingly, increases 
are robustly suppressed by the Src kinase inhibitor PP2 in young but not old mice. 
Phosphotyrosine screening revealed, with aging, a biochemical signature of markedly 
impaired agonist-induced FA remodeling previously associated with Src signaling. 
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Protein expression measurements confirmed a decrease in Src expression with aging. 
Thus, I report here an additive model for the ex vivo biomechanical components of the 
mouse aortic wall in which: 1) VSMCs are a surprisingly large component of aortic 
stiffness at physiologic lengths and 2) regulation of the VSMC component through FA 
signaling and hence plasticity is impaired with aging, diminishing the aorta’s normal 
shock absorption function in response to stressors. 
 
3.3 Introduction 
Aortic stiffness, a biomechanical property of material and structure, is clinically 
assessed using in vivo observations of pulse wave velocity (PWV). Increased PWV is an 
early and independent biomarker of cardiovascular disease. 
It is far from clear how changes in blood vessel properties contribute to observed 
increases in PWV. A mathematical relationship between PWV and vessel stiffness has 
been described by the Moens-Korteweg equation, in which PWV is proportional to the 
square root of elastic modulus, alternatively known as material stiffness (Greenwald 
2007), and also dependent on wall thickness and vessel diameter. However, the Moens-
Korteweg equation is predicated on several simplifying and non-physiologic 
assumptions, including uniformity of vessel composition (Clark and Glagov 1985, 
Gosling and Budge 2003), as well as dynamic values of vessel geometry that are difficult 
to quantify in vivo. Therefore, in order to understand more comprehensively the 
relationship between PWV and aortic material stiffness, it is first necessary to determine 
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ex vivo how changes to material properties of the blood vessel wall and its 
subcomponents contribute to aging-induced increases in aortic stiffness. 
VSMCs may play an important role in effecting and affecting aortic stiffness, 
although their contributions relative to that of ECM and the effects of aging have not 
been ascertained. Here, aortic mechanical properties were directly measured to assess 
aortic stiffness in tissue samples from mice confirmed to contain viable smooth muscle 
cells. I demonstrated that these properties are separable into quantifiable components 
distinguished by activation levels of VSMCs and that, unexpectedly, smooth muscle 
contributes up to half of total material stiffness. These measurements were performed for 
the first time in old mouse aortas using direct mechanical distension to produce 
circumferential strain, in contrast to previous biomechanical studies of old aortas utilizing 
pressurization (Pezet et al. 2008, Philibert et al. 2012). Furthermore, I show that with 
aging, regulatory pathways related to focal adhesion signaling in the smooth muscle cell 
are lost, an effect expected to compromise the ability of the proximal aorta of an old 
mouse to perform its normal function as a hemodynamic shock absorber and maintain 
appropriate stiffness levels in the presence of in vivo challenges. 
 
3.4 Results 
3.4.1 Physiologic optimal length in mouse aorta does not change with age 
The physiologic range of circumferential stretch ratios experienced by mouse 
aorta in vivo during normal blood flow is between 1.5–1.8 (Wagenseil and Mecham 
2012), i.e., a circumferential strain of 50–80%. To select the value within this range most 
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appropriate for stiffness measurements reflective of physiologic VSMC contributions, I 
determined the physiologic optimal length of the tissue, the value for which active force 
production is maximal, both in young and old mouse aortas (Blaustein et al. 2012). This 
was done via analysis of a length-tension curve, normalized to a stress-strain curve, for 
induced aortic vascular smooth muscle contractility. 
At 20% increments of sustained circumferential strain, up to 200% total strain, the 
contraction resulting from 15 minutes’ steady-state equilibration with 51mM KCl PSS 
was recorded. After subsequent washout with Krebs PSS and another 30 minutes of 
equilibration, the tissue was stretched to the next increment of 20% strain. As shown in 
Figure 3.1A, the contractile force production at 80% circumferential strain is not 
significantly different from maximal force production and is also within the in vivo range 
of circumferential strain measured by Wagenseil and Mecham. Furthermore, optimal 
length was determined not to differ between young and old mice. Thus, 80% was used as 
the operating strain for all subsequent ex vivo stiffness measurements. 
The induced contractile stress accounted for approximately half of the total aortic 
stress experienced at the operating strain of 80% and that this proportion is greater in old 
mice, as shown in Figure 3.1B. Therefore, the role of smooth muscle in the makeup of 
total aortic stress is far from trivial, and when fully stimulated, VSMCs contributes 
proportionally more with aging. While this was highly encouraging of a more rigorous 
investigation, I first sought to compare the results of our methodology to those 
established in the literature, which focuses mostly on passive stiffness characterized by 
extracellular matrix. 
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(A) 
 
(B) 
 
Figure 3.1. Physiologic optimal length in young and old mouse aorta. (A) The strain 
level at which maximal contractile stress (kPa) occurs within physiologic ranges of aortic 
strain was determined to be 80% in both young and old mice (n = 3 each). (B) At 80% 
strain, maximal contractile stress constitutes a greater proportion of total stress (53%) in 
old aortas compared to that in young aortas (42%); *, p < 0.05. 
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3.4.2 Baseline aortic wall tension increases with aging at optimal length but 
stiffness decreases 
Measurements from 13 young and 12 old mice demonstrated significant increases 
in average outer vessel diameter at slack length (young: 755 ± 10, old: 936 ± 17 μm, p < 
0.001) and wall thickness (young: 56.9 ± 0.4, old: 76.9 ± 0.9 μm, p < 0.001). Assuming 
cylindrical geometry of each wall at slack length, inner diameter was inferred also to 
increase with age and approximated by subtracting twice the thickness from the outer 
diameter, resulting in means of 641 μm in young versus 782 µm in old. 
Baseline force is defined as that experienced by an aortic tissue sample stretched 
to 80% strain and allowed to equilibrate. The baseline stiffness (elastic modulus) was 
measured as the resultant ratio of change in stress to change in strain in response to high-
frequency low-amplitude (HFLA) changes in length (1% of slack diameter), as a 
sinusoidal oscillatory stretch superimposed upon optimal length. Changes in strain were 
minimized to cause essentially negligible perturbation of the tissue. 
Observed at steady-state after equilibration at optimal length, baseline force 
increased significantly with aging (+34%, p < 0.001) in response to being stretched to the 
operating strain of 80% (Figure 3.2A). In vivo, wall tension is an important parameter, 
particularly under hypertensive conditions, as it has been linked to changes in 
transforming growth factor-β (TGF-β) and NO release from the endothelium (Prado and 
Rossi 2006). When wall tension (Figure 3.2B) is calculated by dividing the measured 
force by axial length, there is also a significant increase with aging (+32%, p < 0.001). 
However, when normalized by cross-sectional area to calculate stress (Figure 3.2C), no  
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Figure 3.2. At optimal length, baseline aortic wall tension increases with aging, but 
stiffness decreases. Values are mean ± SE; ***, p < 0.001. (A) Baseline aortic stiffness 
via stress-strain measurements in the absence of agonist decreases with aging. (B) 
Baseline steady-state force increases with aging. (C) Wall tension, equivalent to force 
normalized to axial length, increases with aging. (D) Stress, equivalent to tension 
normalized to wall thickness, does not change with aging. (E) Baseline aortic stiffness 
via HFLA measurements in the absence of agonist decreases with aging. n = 15 young 
and 18 old for (A), 13 young and 12 old for (B), (C), (D), (E). 
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difference is seen, indicating that vessel geometry is the primary effector of increased 
wall tension. 
I performed small HFLA stretches to calculate stiffness and found that the 
baseline value actually significantly decreased by 16% with aging (p < 0.001) as shown 
in Figure 3.2D. This was surprising given previous reports of increased PWV in old mice 
(Reddy et al. 2003). It is clear that baseline ex vivo material stiffness, calculated as elastic 
modulus, fails to account for aging-induced increases in PWV alone when applied to the 
Moens-Korteweg equation in conjunction with changes in wall geometry. 
 
3.4.3 Ex vivo baseline stiffness does not increase in hypertensive mouse models of 
high-fat-diet and angiotensin II 
Hypertension is closely associated with both aging and increased aortic stiffness. 
Although it was surprising that ex vivo baseline stiffness did not increase with aging, I 
sought to confirm the hypothesis of higher stiffness expected in diseased mouse models 
reflective of hypertensive physiology. 
For the first part of a collaborative study with the Vascular Biology Section at the 
Whitaker Cardiovascular Institute of Boston University Medical Center, I collected ex 
vivo stiffness measurements on aortas extracted from male C57BL/6J mice of two 
different hypertensive model populations. The first population, consisting of ten-month-
old (middle-aged) mice that were fed an eight-month high-fat/high-sucrose (HFHS) diet, 
was also the subject of a published study by the Vascular Biology Section, in which 
significant physiological changes such as increased pulse wave velocity and mean arterial 
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pressure, decreased nitric oxide availability, as well as indication of kidney damage, were 
all observed (Weisbrod et al. 2013). These mice were compared against a set of normal-
diet (ND) controls. The second population consisted of eight-week-old male C57BL/6J 
mice that were infused with a seven-day regimen of subpressor angiotensin II (Ang II), 
which induces downstream hypertensive effects including hypertrophy of the arterial 
medial layer and collagen deposition (Fleenor et al. 2010, Wang et al. 2010). These mice 
were compared against control animals that underwent saline infusion. 
I was surprised to find that neither hypertensive model population displayed an 
increase in baseline stiffness values obtained by HFLA stretch, as shown in Figure 3.3. 
Once again, the anticipated increase in aortic material stiffness through direct 
biomechanical measurements does not occur ex vivo, despite the observation of an 
increase in PWV. 
 
3.4.4 Baseline stiffness increases in Sirtuin-1 knockout mice with angiotensin II 
pretreatment 
The second part of our collaboration with the Vascular Biology Section at the 
Whitaker Cardiovascular Institute of Boston University Medical Center shifted the focus 
from changes predominantly in aortic matrix to those affecting smooth muscle cells, 
specifically a model for Sirtuin 1 (SIRT1) deficiency in VSMCs. SIRT1 is a deacetylase 
that acts on important metabolic regulatory transcription factors and an anti-aging gene 
(Nemoto et al. 2005, Rodgers et al. 2005). The role in vasculature of SIRT1 is not 
entirely clear, but studies have identified SIRT1 as a homeostatic factor in vasculature  
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Figure 3.3. Baseline stiffness does not increase with high-fat diet (A) or angiotensin 
II pretreatment (B). No increase in baseline stiffness was observed in either of two 
diseased mouse models of hypertension against controls. 
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and key correlate of anti-oxidant and anti-inflammatory effects in various organ systems 
(Haigis and Sinclair 2010, Kawai et al. 2011, Yeung et al. 2004, Zhou et al. 2011). In 
mice, SIRT1 in VSMCs has been shown to shield against atherosclerotic and 
hypertensive effects by downregulating angiotensin II type 1 receptor expression, 
attenuating induced vascular remodeling (Gorenne et al. 2013). 
I studied aortas from mutant mice bearing a deletion of SIRT1 (smooth muscle 
knockout, SMKO) that underwent a 5–7 day treatment course with Ang II to observe the 
biomechanical phenotype resulting from the absence of this protection. Upon applying 
HFLA stretch to SMKO mice, as well as wild-type controls, both with saline and Ang II 
infusions, I ascertained baseline stiffness as shown in Figure 3.4. The combination of the 
SIRT1 knockout and Ang II treatment produced a significant increase in baseline 
stiffness. Additionally, my collaborators found excellent consistency between my ex vivo 
measurements and their in vivo pulse wave velocity recordings. 
When considering this outcome in the context of other observations made by the 
collaborators, there emerges a strong motivation to enhance our biomechanical 
understanding of aortic stiffness as pertaining to VSMCs. In SMKO mice, 70% of the 
population die of aortic dissection within two weeks after the beginning of treatment. 
Compared to Ang II wild-type mice, SMKO aortas exhibited significantly less adventitial 
collagen, but oxidant production in cultured VSMCs increased. Furthermore, aortic 
medial thickness decreased, with constituent elastin fibers suffering noticeable 
deformation, in concordance with higher expression of matrix metalloproteinases 
(MMPs) (Fry et al. 2015). These findings show that VSM SIRT1 is vitally important in  
49 
 
Figure 3.4. Sirtuin-1 knockout mice have increased baseline stiffness as measured ex 
vivo (A) and in vivo (B) with angiotensin II pretreatment. *, p < 0.05 versus saline; #, 
p < 0.05 versus wild-type, n = 4–5 for each population. Modified from (Fry et al. 2015).  
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maintaining the integrity of the aortic wall in response to hypertrophic agents such as 
Ang II, and presents critical justification for a more thorough investigation into the role 
of VSM and its regulatory mechanisms in anchoring aortic structure and function. 
 
3.4.5 Increased passive aortic stiffness with aging occurs only beyond physiologic 
strain levels 
Before turning to study VSM contributions to aortic stiffness, I deemed it 
necessary to reconcile the apparent discrepancy between our steady-state baseline results 
and stiffness results from other studies in the literature (Fleenor et al. 2014), I constructed 
stress-strain curves for young and old mouse aortas by subjecting tissue samples to slow, 
high-amplitude ramps spanning a range of strains from 0–250%, well beyond physiologic 
levels and beyond even the upper limit of previously acquired length-tension curves. 
Additionally, I eliminated any possible contributions from VSM by deactivating them in 
a calcium-free environment, mimicking the conditions established in similar studies 
(Fleenor et al. 2012). Passive aortic stiffness values were calculated as the local slopes of 
the stress-strain curve at 25%-strain intervals, with the exception of replacing the 75% 
point with 80% in correspondence with optimal length. 
As shown in Figure 3.5, a significant increase with aging exists in stress and 
stiffness, beginning at strains of 250% and 200% respectively. Between 100–200% strain, 
the stress-strain curve for old aorta appears to overtake that of young aorta, which leads 
to higher stiffness values at higher strains. Thus, these results are compatible with 
increased passive stiffness attributed to old aortas in previous ex vivo studies which  
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Figure 3.5. Passive aortic stiffness via mechanical stress-strain increases with aging 
only beyond physiologic strain range. Stress (A) and stiffness (B) plotted against strain 
for young and old proximal thoracic aortas in calcium-free environment using ramp input 
from slack to failure. No significant difference is observed at low strains, including the 
physiologic range of 50–80%. At higher strain levels, when collagen is heavily recruited 
due to large-amplitude stretching, old aortas are stiffer. n = 6 young, 7 old; values are 
mean ± SE; */**, p < 0.05/0.01. 
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evaluate stiffness at higher strains (Fleenor et al. 2014, Fleenor et al. 2012, Pezet et al. 
2008). Additionally, the stress-strain curve shows a downward trend in baseline stiffness 
with aging at physiologic strain ranges, qualitatively comparable to stiffness measured 
via the HFLA protocol. 
 
3.4.6 Warming aortic tissue from cooled state produces opposite effects on stress 
versus stiffness 
Having ascertained the difference in passive stiffness between young and old 
mice, I sought a better understanding of the distinction between baseline and passive 
stiffness. Previous studies in ferret aorta have defined a temperature-dependent aspect of 
VSMC contractility known as intrinsic tone. Cooling equilibrated vascular tissue 
suppresses the activity and contributions to wall stress and stiffness of VSMCs; this 
process is reversible upon warming the tissue back to body temperature (Pawlowski and 
Morgan 1992). From this, it follows that baseline stress and stiffness should comprise, in 
part, an intrinsic component that is observable by adjusting the environmental 
temperature of viable aortic tissue samples. 
Therefore, in the context of these ex vivo studies, I am able to establish the 
broader notion of a temperature-dependent (t-d) aortic tone as the increase in force 
observed when viable aortic tissue is warmed from a deactivated state (2ºC) to baseline at 
body temperature, which can be normalized to stress using wall geometry. Similarly, t-d 
stiffness is the difference between baseline stiffness and the measurement obtained at a 
cooled (deactivated) state via HFLA stretch. By this definition, t-d stress and stiffness are 
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not direct measurements. Rather, they are relative changes evaluated between two 
discrete observations: the deactivated and baseline states. I performed reversible cooling 
experiments with tissue in smaller sample populations young and old mice, for which 
increases in both stress and stiffness upon warming were expected from each population. 
As shown in Figure 3.6, t-d stress is a positive value, while t-d stiffness is 
negative, a surprising change that was not seen in ferret aorta. In other words, stress 
increases and stiffness decreases when aortic tissue is warmed to baseline from a cooled 
state, highlighting a crucial and previously unstudied qualitative distinction between 
stress and stiffness in mouse aorta. 
While these trends were undoubtedly interesting and provoked consideration of 
subsequent tangents focusing on the composition of stiffness, it was clear that there was 
little additional information to be gleaned from the baseline in search of a discrete 
contribution to total stiffness from VSMCs. Therefore, activation of the smooth muscle 
cells was necessary to advance this objective. 
 
3.4.7 Vascular smooth muscle cells account for up to half of maximal total aortic 
stiffness 
To study the contributions of VSM to aortic stiffness under more typically 
physiological conditions, I activated VSMCs in young and old aortas with PE, then L-
NAME as detailed in Chapter 2.5.4. Steady-state stress and HFLA stiffness values were 
obtained after each equilibration period. I define the active stress and stiffness as the 
increases from baseline observed after addition of PE, reflecting the activation of the 
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A Stress     B Stiffness 
   
Figure 3.6. Warming aortic tissue from cooled state produces opposite effects on 
stress versus stiffness. Warming equilibrated aortic tissue at optimal length to deactivate 
smooth muscle cells induces opposite effects on stress (positive change) (A) and stiffness 
(negative change) (B), observable in young and old mice. Temperature-dependent 
decrease in stiffness is consistent with known properties of collagen. n = 3 young, 4 old; 
values are mean ± SE. 
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smooth muscle cells. Treatment with L-NAME induced no change in baseline stress or 
baseline stiffness values after 30 minutes (< 2% change, ns), indicating that the VSMCs 
must be activated with agonist in order for NOS inhibition to have an effect on stress and 
stiffness, further supporting the concept that the active component is separable and 
necessarily dependent upon agonist stimulation. I define maximal active stress and 
stiffness as the increases from baseline observed after addition of both PE and L-NAME, 
or in purely quantitative terms, the sum of the active and NO-inhibited components. 
No significant difference in the magnitude of the PE effects alone was seen 
between young and old mice (comparing white bars to corresponding black bars in 
Figure 3.7A–B). After 15 minutes of stimulation with PE, I treated aortas with L-NAME 
for an additional 20 minutes, with PE still active. Stress and stiffness significantly 
increased further, as shown in Figure 3.7A–B (p < 0.001). A smaller increase in stress 
resultant from NO inhibition was observed with aging as shown in Figure 3.7A (p < 
0.001), reflecting the probable decrease in endothelial NO production with aging, as has 
previously been reported in other studies (Brandes et al. 2005, Taddei et al. 2001). On the 
other hand, no such difference in L-NAME-induced stiffness increases were seen (Figure 
3.7B). 
When baseline and maximal active components of aortic stress and stiffness are 
plotted to display different fractions of the total, as shown in Figure 3.7C–D, it becomes 
evident that activated aortic smooth muscle (the source of maximal active components) 
accounts for more than half of maximal total stress and approximately half of maximal 
stiffness. 
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Figure 3.7. VSMCs contribute significantly to aortic stress and stiffness at optimal 
length via HFLA method. (A, B) Addition of alpha agonist phenylephrine (PE) 
increases aortic stress and stiffness from baseline values. Further treatment with L-
NAME to remove effects of endothelial nitric oxide further augments these increases. n = 
4 for both young and old; values are mean ± SEM; † indicates a difference with L-
NAME. (C, D) Maximally activated vascular smooth muscle accounts for approximately 
half of maximal total aortic stress and stiffness with aging. Absolute values are mean ± 
SEM. ††† indicates p < 0.001 with addition of L-NAME. 
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3.4.8 Tyrosine phosphorylation of focal adhesion proteins is impaired with aging 
due to decreased Src expression 
Increases in aortic stiffness resulting from VSM activity give rise to the question 
of what molecular mechanisms underlie these contributions. Our group has previously 
shown that focal adhesions play a key role in regulating aortic stiffness (Saphirstein et al. 
2013). The Src kinase inhibitor PP2 suppresses focal adhesion dynamics as measured by 
tyrosine phosphorylation and endosomal recycling of focal adhesion proteins in aortic 
smooth muscle (Min et al. 2012, Poythress et al. 2013). This specifically alters cortical 
stiffness of VSMCs as measured by magnetic-microneedle technology (Saphirstein et al. 
2013). In contractile VSMCs, focal adhesion signaling during cell adhesion events is a 
major source of tyrosine phosphorylation (pTyr) (Romer et al. 2006). The majority of 
remaining phosphorylation events can be attributed to Ser/Thr phosphorylations (Li et al. 
2009). 
Phosphotyrosine levels in PE-stimulated young aortas were measured with the 
assistance of Cynthia Gallant and Qian Qian Lin. Several pTyr bands increased 
significantly in the presence of the agonist (p < 0.05). Past work has identified the 
tyrosine phosphorylated bands in aorta as containing Cas (130 kDa), FAK (125 kDa), and 
paxillin (68 kDa) (Min et al. 2012). This increase was readily inhibited in the presence of 
PP2, an inhibitor of Src kinase (Figure 3.8A). In contrast, the agonist produced no 
significant increase in tyrosine phosphorylation and PP2 produced no statistically 
significant decrease in phosphorylation in old aortas under the same conditions (Figure 
3.8B). 
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     A                   Young pTyr                    B                    Old pTyr 
      
    
 
Figure 3.8. Agonist-induced, PP2-sensitive focal adhesion signaling is impaired in 
old aortas. (A, B) Mean ± SEM of densitometry for pTyr for young and old mouse aortas 
with typical blots shown. Typical gel image brightness was adjusted for visual clarity but 
densitometry was based on raw data. n = 10 young unstimulated, 4 young +PE and 
+PE+PP2, 5 old for each treatment; */**/***, p < 0.05/0.01/0.001. (C) Densitometry of 
c-Src immunoblots of young and old aortic homogenates (n = 3 each). Typical c-Src blot 
shown in inset; bands are from the same gel but have been digitally moved adjacent to 
each other. n = 3 young, 3 old; *, p < 0.05. 
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To investigate further the ineffectiveness of Src inhibition in old aortas, I worked 
with Cynthia Gallant to assay directly expression levels of c-Src by immunoblot analysis. 
Densitometry of c-Src immunoblots of aortic homogenates, as shown in Figure 3.8C, 
revealed a significant decrease in c-Src levels in aged aortas compared to young aortas, 
thus at least in part providing an explanation for the impaired regulation of FA signaling 
in the aortas from old mice. Since tubulin was used in these studies for normalization, the 
possibility arose that tubulin levels could differ with aging. To test for this, tubulin levels 
were quantified in young and old mouse aortas, normalized to another “housekeeping” 
protein, GAPDH, and no significant difference was detectable (young: 0.646 ± 0.149, 
old: 0.509 ± 0.122, n = 12 each, p = 0.48). 
 
3.4.9 Aging impairs action of a Src small molecule inhibitor on aortic stress and 
stiffness 
Since I have previously shown that focal adhesion signaling regulates stiffness in 
young aortas, the biochemical results above predict that the aortas from old mice should 
have impaired stress and stiffness responses to PP2. Thus, I sought to establish the impact 
of inhibition of Src and focal adhesion signaling on stress and stiffness in the context of 
aging. After equilibration at baseline, aortas were treated with PP2 (10 µM), which 
induced no significant change in stress or stiffness after 30 minutes of exposure in either 
young or old aortas (< 2% change, ns). After this pre-treatment, I activated the samples 
with PE for 15 minutes. 
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As previously reported (Saphirstein et al. 2013) and confirmed here, PP2 reduced 
active stress and stiffness in young aortas, but in marked contrast, the Src inhibitor 
produced no significant change in the maximal active stress of old aortas (-2%, ns) and a 
slight decrease in maximal active stiffness (-14%, p < 0.05). In comparing young and old 
samples I found that, in the presence of PP2, maximal active stress (Figure 3.9A) and 
stiffness (Figure 3.9B) of old aortas are more than twice those of young aortas. Thus, the 
ex vivo removal of the regulatory mechanism of focal adhesion signaling which normally 
is able to decrease stiffness in young vessels leads to a high stiffness state in old vessels, 
reminiscent of the increased PWV measurement in vivo in old vessels (Reddy et al. 
2003). 
 
3.4.10 Aging-induced impairment of Src-mediated regulation of active stiffness in 
mouse aorta begins between 14–24 months of age 
As a brief footnote to these findings, our group has recently begun to construct an 
aging curve to track the deterioration of Src-mediated regulation of active stiffness. In 
collaboration with Diana Zhang, medical student at Boston University School of 
Medicine, we repeated PP2 inhibition experiments on a set of young C57BL/6J mice 
using the same protocol, then followed with mice from two age populations previously 
not investigated: 14 months and 24 months. These correspond to the upper limits of 
“middle-aged” and “old” ranges depicted in Figure 2.1 equivalent to 47 and 69 human 
years respectively (Flurkey et al. 2007). In this work, I will instead refer to these two 
groups as “early middle-aged” and “late middle-aged” mice to make the distinction from  
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Figure 3.9. Agonist-induced increases in aortic stress and stiffness with Src kinase 
inhibitor pretreatment are higher with aging. Thoracic aortas pre-treated with 10 μm 
PP2 contract and stiffen less in young but not old mice in the presence of maximal 
activation (PE plus L-NAME). As a result, maximal active stress (A) and stiffness (B) 
increase more than twofold with aging under these conditions with HFLA measurements. 
Also shown for comparison are control maximal active data in the absence of PP2 (PP2-), 
reproduced from Figure 3.7A–B. Absolute values are mean ± SEM; n = 3 young, 4 old; 
*** indicates p < 0.001 with aging; ‡/‡‡‡ indicates p < 0.05/0.001 with addition of PP2. 
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“old” 29-month mice. 
Data as shown in Figure 3.10 suggest that initial decline in normal VSMC-
dependent function of the Src pathway occurs between the early and late middle-aged 
states. PP2 pretreatment successfully induced knockdown of PE-induced stress and 
stiffness increases in 3- and 14-month-old mice, but by 24 months of age, Src inhibition 
was no longer effective. These data provide a framework for further biomechanical and 
biochemical inquiry. 
 
3.5 Discussion 
3.5.1 Additive model of aortic stress and stiffness consists of separable components 
that highlight major contributions from vascular smooth muscle cells 
A major finding of the present study is that the smooth muscle cell is a major 
source and regulator of vascular stiffness, in contrast with the often assumed dominance 
of extracellular matrix in effecting changes in wall stiffness with aging (Greenwald 
2007). Activated VSM has previously been incorporated into mathematical models of 
vessel stiffness derived from pressurization studies (Gleason et al. 2008, Rachev and 
Hayashi 1999). Furthermore, it is known from the literature that in the peripheral 
vasculature, the level of VSM activation has a dramatic effect on its load-bearing 
capabilities (Bank et al. 1996). 
Here I quantified directly the contributions from VSM activation as percentages 
of total stiffness in an additive model established from real-time observations of force 
responses to mechanical uniaxial stretch and subsequent normalization to elastic  
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A Stress    B Stiffness 
 
Figure 3.10. Src-mediated regulation of active aortic stress (A) and stiffness (B) is 
likely defective by 24 months of age in C57BL/6J mice. PP2 effectively inhibits 
agonist-induced stress and stiffness increases at 3 and 14 but not 24 months of age. n = 5 
at 3 months, 4 at 14 months, and 3 at 24 months. *, p < 0.05 by Student’s t-test. 
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modulus. The components of the model, defined and separable under our experimental 
conditions, are presented visually in Figure 3.11, incorporating timescales of a typical 
experimental trace. These findings establish a new perspective in evaluating the relative 
importance of different biomechanical components in the aortic wall and especially 
emphasize the large proportion of maximal total stiffness supervised by active VSMCs. 
 
3.5.2 Baseline aortic stiffness establishes important mechanistic links between 
vascular smooth muscle cells and extracellular matrix proteins 
Baseline stiffness is defined here to reflect the biomechanical properties of an ex 
vivo aortic sample without agonist activation of the VSMCs. It is largely characterized by 
extracellular matrix (ECM), consistent with the lack of change in baseline mechanical 
properties under either PP2 or L-NAME treatment. Nevertheless, it is important to note 
the distinction between “baseline” and “passive” in that baseline reflects a non-zero 
contribution from VSMCs. Our initial hypothesis—that “intrinsic” tone of aorta, defined 
by Pawlowski et al. as the VSMC component of baseline measurable by reversible 
cooling, is the sole “temperature-dependent” component of baseline—was disproven by 
the negative change in stiffness that accompanies the warming of tissue from 2–37º C. 
The t-d component of baseline characterizes not only VSMCs but also matrix, consistent 
with known material properties of elastin and collagen. In a previous study of porcine 
aortic wall, at least 2000 indentations of both media and adventitia revealed a trending 
decrease in elastic modulus when warming from room temperature (25º C) to body 
temperature (37º C) (Beenakker et al. 2012). Furthermore, type I collagen has been  
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Figure 3.11. Additive model of aortic stress and stiffness consists of separable 
components. (A) Representative result stress trace for young mouse aorta with scale for 
time and typical magnitudes of stress showing matrix-dominant baseline (blue), 
separable from active and NO-inhibited smooth muscle components. Maximal active, 
intact total, and maximal total stress are obtained by summing combinations of the 
three basic components. Baseline further comprises deactivated and temperature-
dependent components; the latter is the observable change from the former by warming 
to body temperature. (B) Stiffness measurements were made at marked time points along 
trace from force responses to high-frequency (40 Hz), low-amplitude oscillations in 
length. Proportions of analogous stiffness components for young mouse aorta at 37º C 
shown, with scale for typical magnitudes. 
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shown to be thermally unstable, likely to enable melting and refolding of helices to 
provide extra fiber strength and elasticity (Leikina et al. 2002). Therefore, the 
“deactivated” stress and stiffness of aortic tissue observable in its cooled state reflects 
passive matrix elements, but not the entirety of those that make up the baseline. 
Indeed, the studies conducted on SMKO mice indicate that VSMCs and elastin 
harbor an especially important codependent link, with elastin regulating VSMC 
proliferation (Brooke et al. 2003) and SIRT1 playing a critical and potentially necessary 
role in maintaining structure and preventing dissection (Fry et al. 2015). The chronic and 
severe disorganization and fragmentation of elastin fibers caused by the SMKO result in 
“brittleness,” a characterization of the wall observable when equivalent strains on the 
vessel produce higher stresses, as well as higher baseline stiffness values. This induces a 
propensity to dissect during blood flow due to the aorta’s inability to accommodate these 
higher stresses. Recently, others have found that while the medial layer in mouse aorta 
thickens with aging, resulting in lower cellular density and higher collagen content, the 
amount of elastin did not change significantly (Wheeler et al. 2015). One interpretation of 
this finding is that the altered structure of the media weakens formerly stable linkages 
between VSMCs and elastin due to the interference of collagen. 
On the other hand, acute agonist-induced effects are attributed solely to aortic 
VSMC contributions to stress and stiffness and can be further parsed into those that occur 
with and without the presence of endothelial nitric oxide production, respectively. 
Establishing such discrete quantities provides a way to compare the relative importance 
of different biological constituents of the aortic wall in their contributions to aortic stress 
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and stiffness. Our results demonstrate that when activated, VSMCs are undeniably 
significant effectors of both total aortic stress and vascular stiffness and, interestingly, are 
strongly subjected to persistent regulation by endothelial nitric oxide production. 
 
3.5.3 Impaired regulation of shock absorber function by focal adhesions and non-
muscle cytoskeleton is a source of increased aortic stiffness with aging 
In old aortas, the inefficacy of PP2 implicates focal adhesions (FAs) as a site of 
defective cellular signaling with aging. It has previously been shown that Src-dependent 
aortic focal adhesion signaling and focal adhesion cycling play a critical role in 
regulating stress and stiffness induced by activation of VSMCs in young mice (Poythress 
et al. 2013, Saphirstein et al. 2013). I show here that old mice lose the response to the 
inhibitory effects of the Src inhibitor PP2 on agonist-induced stress, stiffness, and 
phosphotyrosine increases. 
These results can be framed within the context of total aortic VSMC 
biomechanics as shown in Figure 3.12. The attachment of myosin cross bridges to actin 
in activated smooth muscle cells is a major component of agonist-induced stress and 
stiffness increases in VSMCs, while focal adhesions are known to play the important role 
of linking the contractile filaments, through the non-muscle cytoskeleton (NMC), to the 
extracellular matrix and the vessel wall via integrins. Alpha agonists as shown here and 
in past studies of VSM regulate both the contractile filaments and the FAs (Kim et al. 
2008, Saphirstein and Morgan 2014). Normal FAs in young aortas provide the capacity to 
regulate their maturation cycles and their connections to the NMC to accommodate  
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Figure 3.12. Shock absorption via Src-mediated focal adhesion/non-muscle 
cytoskeleton regulation is defective in old aortas. Model of how changes in stiffness 
generated by cross bridge attachment and remodeling of focal adhesions and non-muscle 
cortical cytoskeleton can be regulated by a PP2-sensitive mechanism present in young but 
not old aortas. Abbreviations: FA: focal adhesion; NMC: non-muscle cytoskeleton; 
MLCK: myosin light chain kinase. 
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changes in vessel stress and stiffness and provide, in essence, shock absorption against in 
vivo hemodynamic events. A similar mechanism proposing independent co-activation of 
cytoskeletal remodeling and cross bridge cycling has been proposed for airway smooth 
muscle (Gunst and Zhang 2008, Zhang and Gunst 2008). The NMC-FA remodeling 
regulatory pathway and its consequent potential for shock absorption function is lost in 
old mice. 
Recently, our group has shown that the regulatory role of NMC extends to venous 
stiffness (Saphirstein et al. 2015). Experiments using ferret portal vein that agonist-
induced increases in cortical stiffness in freshly-isolated contractile VSMCs are 
attenuated by inhibitors of actin polymerization (cytochalasin D; CytoD) but not Src 
(PP2), although increases in tissue stiffness are inhibited by both. This points to the 
existence of a cortical actin “switch” that is regulated by an agonist such as PE and 
promotes transmission of force and stiffness from the contractile machinery inside 
VSMCs through the FAs to the ECM. Also implied is the existence of at least some 
regulatory factors of stiffness within the FA-NMC complex that are independent of one 
component or the other. Unlike with tissue stiffness, FAs do not appear to regulate 
cortical stiffness directly; PP2 did not reduce PE-induced increases in cortical stiffness, 
measured with magnetic-microneedle technology (MT), and FA size (approximately 20 
µm² in area) did not change with PE stimulation (Saphirstein et al. 2015). Furthermore, 
signaling through the FAK-Src complex was found to affect downstream phosphorylation 
of caldesmon (CaD) by extracellular-signal-regulated kinase (ERK). CaD is a protein 
that, when unphosphorylated, binds actin filaments to inhibit actomyosin interactions. 
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Phosphorylation of CaD by ERK1/2 disinhibits actin, increasing its availability and 
augmenting cross bridge cycling (Huang and Wang 2006, Lee et al. 2000, Li et al. 2009). 
We found that PE induces an increase in phospho-ERK levels inhibitable by PP2, 
reinforcing the importance of Src as a regulator of VSMC signaling pathways that 
contribute to aortic stiffness (Saphirstein et al. 2015). 
As a result, it is necessary to improve the FA-NMC regulatory model to 
distinguish between FA- and NMC-oriented signaling pathways and connect FA 
signaling to actomyosin contractility. These conclusions are summarized in Figure 3.13, 
with the caveat that they are valid in ferret portal vein cultured VSMCs and not 
necessarily non-cultured VSMCs in mouse aorta. In particular, we have yet to ascertain 
thoroughly the differences between aorta and portal vein with respect to effects of PP2. 
Given that PP2 inhibits tissue stiffness in aorta and does not inhibit cortical stiffness in 
portal vein, a clarifying study on whether PP2 does inhibit aortic cortical stiffness using 
MT is warranted. If it does not, then additional factors that affect focal adhesion 
dynamics at the tissue level must be considered. Nevertheless, this expanded model 
putatively elaborates upon the preliminary mechanistic account of aortic shock absorption 
that I provided in my aging study. 
Any aging-impaired protective mechanism fulfilled by vascular smooth muscle 
cells are more likely to be native in the aorta rather than the peripheral vasculature, given 
the relative lack of increase in peripheral pulse wave velocity with aging (Mitchell 2008). 
In aorta, focal adhesions are coupled with the role of the non-muscle cytoskeleton to link 
smooth muscle cell cross bridge activity to extracellular components of the aortic wall.  
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Figure 3.13. Contractile activation of venous smooth muscle alters engagement of 
the cell-matrix adhesion via cortical actin switch and facilitates ERK activation via 
Src (Saphirstein et al. 2015). (A) Diagrammatic view of unstimulated cell shows that 
the non-muscle cortical actin cytoskeleton linked to the focal adhesions is disengaged 
from a population of the contractile filaments. (B) Agonist (phenylephrine; PE) activation 
activates two important signaling pathways: first, the promotion of Src, resulting in the 
facilitation of downstream signaling to extracellular-signal-regulated kinases (ERKs) and 
caldesmon (CaD) phosphorylation, which lead to contractility and stiffening due to cross 
bridge attachment; and second, an increase in cortical non-muscle actin polymerization to 
increase the engagement (the “actin switch”) of the non-muscle cortical cytoskeleton with 
the contractile filaments. These pathways are inhibited by PP2 and CytoD respectively, 
which act correspondingly on Src and actin polymerization. 
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The adhesion-cytoskeleton complex acts as an adaptive shock absorber that readily 
accommodates increases in material stiffness with smooth muscle activation. Focal 
adhesion regulation of actomyosin contractility is likely defective with aging, resulting in 
the reduced capacity for this complex to attenuate aortic stiffening, correlative with other 
structural and functional changes in the vascular smooth muscle cells, as well as 
extracellular matrix proteins. Therefore, the focal adhesions and non-muscle cytoskeleton 
of vascular smooth muscle cells represent potential therapeutic targets in the context of 
preventing or reversing increases in aortic stiffness. The reasons are four-fold: first, the 
smooth muscle cell is a major contributor to and regulator of stiffness at physiologic 
lengths, as shown here; second, agonist activation of smooth muscle promotes changes in 
non-muscle cytoskeleton in response to increased contractility; third, a Src small 
molecule inhibitor is sufficient to counteract stiffness increases at the tissue level through 
focal adhesion remodeling and downstream effects on signaling; and fourth, this capacity 
is diminished with aging. Greater understanding of these mechanisms may facilitate 
future biomedical developments to reverse this aging-induced deficiency. 
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Chapter 4: Cell-Permeable Decoy Peptides Target Focal Adhesion 
and Cytoskeletal Regulation of Aortic Stiffness 
 
4.1 Summary 
Having revealed critical regulatory factors of aortic stiffness in vascular smooth 
muscle that are impaired with aging, I proceeded to explore synthetic therapeutic options 
designed to compensate for these defects. In past studies, members of our group have 
used novel constructs and techniques to probe vascular smooth muscle cell activity, 
deliverable via attachment to molecules known as cell-permeable decoy peptides, which 
are able to penetrate the cell membrane. Here, I used two previously developed peptides 
with the potential to act upon active (smooth muscle mediated) aortic stiffness concordant 
with the biologically mechanistic model developed from my aging study: one inhibits 
focal adhesion protein-protein interactions, possibly restoring the normal function of the 
smooth muscle shock absorber; while the other inhibits actin polymerization, a key 
process governing the dynamics of the non-muscle cytoskeleton in smooth muscle cells. I 
evaluated these two peptides by performing ex vivo stiffness experiments on young and 
old aortas to observe their effects on active stiffness. The decoy peptide targeting focal 
adhesions proved to be effective in both young and old aortas, supporting our biological 
model and presenting strong, if possibly non-specific, therapeutic potential meriting 
further investigation, while the peptide targeting actin polymerization showed promise in 
young aortas but requires additional experiments to resolve its consequence with aging. 
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4.2 Introduction 
Cell-permeable peptides (CPPs), alternatively known as cell-penetrating peptides 
or transduction peptides (Joliot and Prochiantz 2004), describe a class of peptide 
molecules that can translocate through cellular membranes and act as delivery vectors 
into the cytoplasm and nucleus by tethering normally impermeable cargoes, ranging in 
size from DNA fragments and nanoparticles to larger proteins (Heitz et al. 2009, Joliot 
and Prochiantz 2004). Two important characteristics broadly define all known CPPs: they 
are amphipathic and positively charged at physiologic pH, (Zorko and Lagnel 2005). The 
TAT (transactivator of transcription) peptide of human immunodeficiency virus 1 (HIV-
1) is among the most diverse and widely used among all CPP candidates (Gupta et al. 
2005, Heitz et al. 2009, Zorko and Lagnel 2005). Our group has shown that TAT is 
usable as a delivery mechanism for actin monomers into VSMCs to monitor 
polymerization (Kim et al. 2010). In light of these previous findings, as well as the 
recognition from my aging study of focal adhesions and non-muscle cytoskeleton as 
components of a protective mechanism enacted by VSMCs upon the aortic wall, I used 
two CPPs previously developed by Robert Saphirstein of our group, TLN-VBS and N-
WASP-CA, as candidates of interest for inquiry into potential synthetic regulators of 
increased aortic stiffness resulting from activation of VSMCs. 
Previously, Saphirstein designed a TAT-decoy peptide construct, TLN-VBS, 
which targets and disrupts FA protein-protein interactions by competitively inhibiting a 
binding site for vinculin on talin. Vinculin is a structural component of focal adhesions 
that undergoes conformational changes from closed to open when activated and interacts 
75 
directly with talin and actin (Ziegler et al. 2006). Talin links transmembrane integrin to 
actin and, when bound to vinculin, crosslinks with additional actin to reinforce focal 
adhesions (Mierke 2009). Talin has 11 binding sites for vinculin (Critchley 2009), as 
shown in Figure 4.1, three of which were selected for synthesis of CPPs designed to 
compete with talin for vinculin and inhibit focal adhesion reinforcement. Figure 4.2 
features a schematic for this mechanism of action. From the three, I selected the one that 
had demonstrated localized uptake under fluorescent microscopy in cultured cells, as well 
as a lower ratio of cell attachment on an adhesion assay (Saphirstein 2013). This 
suggested reduced focal adhesion development under this treatment and motivated its 
usage in stiffness experiments. 
The second peptide candidate designed by Saphirstein targets actin 
polymerization and branching within the non-muscle cytoskeleton (Saphirstein 2013). 
The Arp2/3 protein complex, regulated by neuronal Wiskott-Aldrich Syndrome protein 
(N-WASP), forms branched actin networks and has been shown to regulate contractility 
in airway smooth muscle (Gunst and Zhang 2008, Zhang et al. 2005). While it has not 
previously been used in studies of intact vascular smooth muscle, N-WASP-CA—the 
peptide used in this study, consisting of the domain in full-length N-WASP that binds 
Arp2/3 (Gunst and Zhang 2008)—has previously been used by our group to demonstrate 
blockage of agonist-induced actin polymerization in cultured cells (Kim et al. 2008). 
Using these CPPs as drug analogs, I conducted ex vivo stiffness experiments to 
assess the effect of TLN-VBS on the active components of stress and stiffness as I 
previously defined in the additive model detailed in Chapter 3.5.1. 
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Figure 4.1. Talin domain map. Talin is a well-studied focal adhesion protein and plays 
a critical role in the regulation of binding to both vinculin and integrin, particularly in the 
F3-talin rod domains. Its 11 binding sites for focal adhesion structural protein vinculin 
are indicated in red. Modified from (Critchley 2009). 
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Figure 4.2. Conceptual diagram of cell-permeable decoy peptide mechanism 
targeting focal adhesion structural proteins (Saphirstein 2013). The TAT 
(transactivator of transcription) tag guides a fluorescently-labeled peptide across the 
smooth muscle cell membrane (1) and targets a focal adhesion structural protein within 
the cell (2) to disrupt its normal protein-protein interaction within the focal adhesion, 
weakening it to reduce vascular tissue stiffness (3). This mechanism of action can be 
generalized for the neuronal Wiskott-Aldrich syndrome protein (N-WASP) peptide, 
which seeks to inhibit actin polymerization. 
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4.3 Results 
4.3.1 Talin-vinculin binding site cell-permeable peptide inhibits active aortic 
stiffness in young and old mice 
From the aging study I conducted previously, I extracted a database of absolute 
values for baseline stiffness and agonist-induced stiffness increases without any 
inhibitory treatment in young and old mice. For this reason, I normalized the results from 
CPP experiments to express active stress and stiffness as percentages of the values 
obtained without any peptide. This streamlined the evaluation of the scrambled form of 
the peptide as an effective negative control for the active form. The experimental protocol 
adhered closely to the established high-frequency low-amplitude (HFLA) procedure, with 
the additional complexity of a treatment-loading step, designed to minimize drug usage 
while maintaining to the best of my ability all other conditions characterizing the original 
protocol. The details of this protocol have been described previously in Chapters 2.6.2 
and 2.6.3. 
My experiments revealed that the CPP TLN-VBS significantly inhibits increases 
in aortic steady-state stress and stiffness induced by both KCl depolarization and PE 
activation at the concentration of 100 µM in both young (3-month) and old (29-month) 
male C57BL/6J mice, and that the scrambled form of TLN-VBS does not, thus serving as 
an effective negative control. There are two novel aspects to these findings, summarized 
in Figure 4.3, with respect to the previously presented aging study: first, that TLN-VBS 
is effective in reducing KCl-induced as well as PE-induced increases in stress and 
stiffness; and second, that it is also effective in old aortas. As shown in Figure 4.3C–D,  
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 A Young KCl    B Young PE 
   
 C Old KCl    D Old PE 
   
Figure 4.3. Talin-vinculin binding site (TLN-VBS) CPP inhibits active aortic stress 
and stiffness in young and old mice. Active-form TLN-VBS inhibits increases in aortic 
stress and stiffness due to smooth muscle activation by KCl as well as PE in young (A, B) 
and old (C, D) mice. Values are plotted as percentages of active stress and stiffness 
observed in tissue experiments without loaded peptide, showing that scrambled-form 
TLN-VBS suffices as a negative control. In old mice, there is no difference in potency 
between 100 and 250 µM. n = 5 each for 100 µM, 3 each for 250 µM; */**/***, p < 
0.05/0.01/0.001 by unpaired Student’s t-test versus scrambled form of the same 
concentration. 
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there was evidence that the peptide did not inhibit active increases in old aortas as well as 
in young aortas (only ~40% inhibition versus ~60%), although there was no significant 
difference between the two effects. Still, this prompted the question of whether TLN-
VBS had reached maximum potency in old mice at 100 µM. Therefore, I followed with 
experiments using 250 µM scrambled- and active-form peptide in old animals and found 
evidence for a stronger average effect (~65% inhibition of stress and ~70% inhibition of 
stiffness), although no statistically significant difference from 100-µM inhibition was 
observed. 
 
4.3.2 Neuronal Wiskott-Aldrich syndrome protein cell-permeable peptide inhibits 
active aortic stiffness in young mice 
Repeating the procedure with the CPP N-WASP-CA, I amended the methodology 
slightly, producing a time course for active stress and stiffness, after the initial addition of 
agonist. The time course provides the ability to identify potentially phasic and tonic 
contractile phases, which are known to occur in smooth muscle in response to agonist 
stimulation (Thornbury 1997, Webb 2003), and also observed to a limited extent in other 
VSM studies performed by our group (Saphirstein et al. 2015). 
As shown in Figure 4.4, the scrambled form of N-WASP-CA is a suitable 
negative control, and the active form, which inhibits actin polymerization, is able to 
inhibit active stress and stiffness induced by PE in young mouse aortas at the 
concentration of 250 µM, chosen as presumed to be at or closer to maximal potency, 
following the results obtained with TLN-VBS. Here, the data were normalized to the  
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A Young Stress (250 μM)   B Young Stiffness (250 μM) 
 
C Old Stress (250 μM)    D Old Stiffness (250 μM) 
  
Figure 4.4. Neuronal Wiskott-Aldrich syndrome protein (N-WASP-CA) CPP 
inhibits active stiffness in young mice. Active-form N-WASP-CA (250 μM) inhibits 
increases in aortic stress (A) and stiffness (B) due to smooth muscle activation by PE. 
Values are plotted along a time course as percentages of 15-minute steady-state active 
stress and stiffness observed in tissue experiments without any peptide loaded, 
demonstrating that scrambled-form N-WASP-CA also suffices as a negative control. 
Time points: 30 seconds, 2 minutes, 5 minutes, 10 minutes, 15 minutes. n = 4–5 each; *, 
p < 0.05 by unpaired Student’s t-test. 
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equilibrated value of active stress and stiffness, observed with no peptide, 15 minutes 
after PE stimulation. 
Further study is necessary to determine if this holds true in old aortas; there was 
no significant effect of this peptide in active form in old mice at the time of this writing, 
with low sample size and high variability providing inconclusive results. Additionally, a 
more robust potency study is necessary to ascertain whether the desired effects might be 
achievable with a lower peptide concentration. 
 
4.4 Discussion 
4.4.1 TLN-VBS inhibition of active stiffness in old mice demonstrates therapeutic 
potential and motivates further investigation of focal adhesion shock absorption 
The initial success in using TLN-VBS and N-WASP-CA CPPs to reduce active 
stress and stiffness is encouraging of further exploration into cellular regulatory 
mechanisms of stiffness as well as the efficiency and efficacy of these decoy peptides. 
My findings from the TLN-VBS loading experiments were especially promising. 
This peptide has not only emerged as an effective inhibitor of active stiffness in old 
aortas but also clarified certain aspects of aging-induced dysfunction of focal adhesion 
regulation. The ability to use TLN-VBS in order to regulate active stress and stiffness 
implies that focal adhesion dynamics, resulting from vinculin binding to talin linkages 
between actin and integrins, are “stuck” in a state disallowing normal aortic shock 
absorption in response to contractile stimuli. It remains to be seen if this is 
mechanistically linked to the defective Src pathway associated with aging, or if it is 
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indicative of altogether different of cellular processes. In other words, the question arises 
as to whether the targeting of TLN-VBS bypass defective signaling of Src, as well as 
phosphotyrosine levels further downstream. Regardless, this novel approach to regulate 
tissue stiffness may indeed form the basis for a therapeutic drug that compensates for the 
loss of normal smooth muscle mediation of increases in aortic stiffness. 
To reinforce the biological rationale for usage of TLN-VBS, our group plans to 
confirm the hypothesis of its action. Using magnetic-microneedle technology (MT), we 
will probe the cortical cytoskeleton of differentiated vascular smooth muscle cells 
(dVSMCs) to assess whether TLN-VBS affects cortical stiffness. To test the molecular 
mechanism, we will use proximity ligation assays (PLA) at a resolution of 200 nm to 
determine if the distance between talin and vinculin within dVSMCs has increased, as 
well as immunoprecipitation (IP) to determine if talin-vinculin binding decreases, in the 
presence of the TLN-VBS CPP. Our group has previously published usage of the MT, 
PLA, and IP techniques in dVSMCs (Poythress et al. 2013, Saphirstein et al. 2013, 
Vetterkind et al. 2013) and we expect positive results from these assays. 
In the previous aging study, I did not examine the effect of PP2 on effects of KCl 
depolarization of VSM, which was performed on strictly to confirm viability before pre-
treatment with PP2 in order to assess its effect on PE-induced increases in stress and 
stiffness. Conversely, it was necessary to perform the peptide-loading protocol before any 
viability contraction with KCl (Chapter 2.7.3). As a result, I obtained KCl-induced 
contractility and stiffening data in the presence of active-form CPPs and found that TLN-
VBS also effectively inhibits this type of active stiffness. This strongly implicates a role 
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for focal adhesions in mediating stiffness increases consequent upon cross bridge cycling 
and also that the model we established in our study of ferret portal vein (Chapter 3.5.3), 
which establishes the ERK1/2 pathway downstream from Src as the conduit for this 
regulation, is valid in mouse aorta. Therefore, another avenue of inquiry is to confirm this 
hypothesis in future subcellular studies. 
 
4.4.2 Future studies are required for confirmation of N-WASP-CA efficacy and 
further pharmacological considerations 
On the other hand, N-WASP-CA has not yet been confirmed to regulate aortic 
stiffness in old mice. Unlike with TLN-VBS, there were additional methodological 
factors in the usage of N-WASP-CA that rendered the peptide loading technique prone to 
significant human error. Specifically, I had to confront significant difficulties in 
preserving physiologic pH during the peptide loading procedure, which may have led to 
decreased drug potency or inconsistent smooth muscle viability across experiments with 
both active and scrambled forms of peptide. There are three distinct contexts in which 
this challenge presents itself: the dissolution of the peptide during preparation of the 
loading solution; the actual loading technique, in which the tissue is transferred into the 
temporarily deoxygenated loading solution; and, after loading, the maintenance of 
oxygenation for the experimental apparatus itself. Measuring the pH of the small loading 
volume in real time is difficult and is currently only practical before and after loading, 
which does not account for changes that may take place during the procedure. Therefore, 
the design of a more accessible apparatus may be necessary in order to enable persistent 
85 
supervision of pH within the loading volume. 
Upon establishment of cellular targets and effective peptides, a more thorough 
pharmacological analysis should be conducted to address important considerations in 
developing a clinical product. For example, although I found that 100 µM was not the 
maximal dosage for TLN-VBS, it may also not be the minimal concentration at which it 
is effective in regulating aortic stiffness in old aortas. To elucidate the potency of TLN-
VBS, a dose response curve for should be constructed after additional data collection. 
Furthermore, I also cannot assume that either peptide used in these studies is effective at 
early-middle or late-middle age. Complementary to the preliminary results of middle-
aged mice presented in Chapter 3.4.10, future studies should also incorporate aortas from 
mice at 14 and 24 months of age. Finally, consideration of drug specificity, with respect 
to both the actual target as well as mechanism of action, should warrant the investigation 
of alternative supply methods into the smooth muscle cells, either through synthesis of 
other peptide configurations, or different delivery methods altogether. 
In summary, many additional ex vivo trials may be needed, but a thorough 
experimental regimen will enable a more complete portrayal of aging-induced changes of 
cellular mechanisms, as well as how decoy peptides might counter any corresponding 
defects in the capacity of smooth muscle to regulate aortic stiffness. 
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Chapter 5: Assessment of Applied Biomechanical Methods in 
Evaluation of Ex Vivo Aortic Stiffness 
 
5.1 Summary 
Before concluding this dissertation with recommendations for prospective 
research endeavors, it is necessary to turn a more critical eye to the biomechanical 
methods employed in these studies of ex vivo aortic stiffness. Here, I review existing 
quantitative models for arterial stiffness and identify the ones most consistent with the 
new findings I presented in the previous two chapters. Subsequently, I provide a thorough 
analysis of the ability to evaluate aortic stiffness precisely with my experimental 
apparatus and techniques, as well as how one might address inherent methodological 
limitations. Finally, I discuss possible reconciliation of discrepancies between clinical 
interpretations of functional stiffness and ex vivo material stiffness as I have studied in 
this dissertation. In conducting this analysis, I hope to establish guidelines and context for 
future studies of vascular smooth muscle contributions to aortic biomechanical 
properties. 
 
5.2 Quantitative Modeling of Vascular Smooth Muscle Contributions to Total 
Aortic Stiffness 
5.2.1 Concurrence with Presented Discoveries 
A relatively small proportion of the literature detailing mechanical properties of 
vascular tissue accounts for any activation of smooth muscle cells (Holzapfel and Ogden 
2010), but even extensive quantitative models focusing primarily on extracellular matrix 
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acknowledge that mechanotransductive responses of VSMCs to blood flow and pressure, 
as well as external phenomena affecting vessel growth, are integral to understanding fully 
the complex dynamics of aortic biomechanical properties. In fact, damage to the VSMCs 
inflicted by cardiovascular disease may be the primary trigger for deterioration of normal 
structure and function in maintenance of the aortic wall (Wagenseil and Mecham 2009). 
It is beyond the scope of this dissertation to develop a rigorous and 
comprehensive model encapsulating all components of the aortic wall, as my studies have 
focused primarily on emphasizing significant contributions to total aortic stiffness from 
VSM under physiologic conditions, rather than establishing a broad spectrum of the 
interplay between VSMCs and other wall components. Indeed, previous studies concede 
that aortic stiffness, in the form of incremental elastic modulus, has no singular 
representative value due to the nonlinearity of stress-strain or pressure-strain responses; 
this nonlinearity is reflected in geometric, compositional, and environmental conditions 
that render opaque the exact dimensional and structural state of the aorta at any given 
moment (Barra et al. 1993, McVeigh et al. 2007) Instead, I sought out two models 
developed from previous research with an explicit focus on VSMCs that are most likely 
compatible with my ex vivo measurements of aortic stiffness in young and old mice. 
 
5.2.2 Vascular Smooth Muscle Cells as Protective Dampers in a Modified Maxwell 
Model of Total Aortic Stiffness 
One study led by Barra and Armentano proposed a modified Maxwell model of 
the incremental elastic modulus of descending thoracic aorta in dogs, consisting of 
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passive springs comprising elastin and collagen (multiple springs progressively recruited 
as strain increases), both in parallel with an active VSMC component, featuring an 
underdamped spring as an elastic element and viscous force-generating contractile 
element in series (Barra et al. 1993). This model was initially developed by Dobrin and 
Canfield in dog carotid artery (Dobrin and Canfield 1977). Barra, Armentano, and their 
collaborators found via an isobaric pressure-diameter study that the majority component 
of total aortic stiffness shifts from elastic to smooth muscle cells as pressure increases 
(Barra et al. 1993). During their in vivo study, they observed decreases in total stiffness 
with PE stimulation under isobaric conditions and recommended isometric analysis—
such as that applied to the stiffness measurements I made at sustained physiologic 
strain—as a more accurate reflection of agonist-induced stress and stiffness increases. 
Interestingly, they also concluded that their model fit the data well and that at very high 
levels of constant pressure, agonist-induced decreases in stiffness reflected a 
compensatory mechanism endowed by the VSM. Therefore, this simple modified 
Maxwell model stands out as one worthy of emulation when integrating physiologic 
stiffness measurements featuring activated VSM. 
 
5.2.3 Vascular Smooth Muscle Recruitment of Collagen 
In a series of publications by Alan J. Bank, based upon studies of brachial arteries 
in humans, a similar model of aortic stiffness is established. This variant of the modified 
Maxwell model couples the VSM to collagen in load-bearing duties. Arterial compliance 
was evaluated in vivo by relating pressure to arterial cross-sectional area as measured by 
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ultrasound catheter under conditions of baseline, as well as vasodilation and 
vasoconstriction through administration of norepinephrine and nitroglycerin respectively, 
then converted to incremental elastic modulus (Bank et al. 1999, Bank et al. 1995). 
Bank and his collaborators concluded by fitting their data that the underdamped 
spring featured in the Barra-Armentano model is actually a collagen element in series 
with the contractile element of VSMCs, and that, similar to the parallel collagen element, 
is progressively recruited as arterial strain increases (Bank et al. 1996, McVeigh et al. 
2007). Contrary to the findings in the Barra-Armentano study, Bank et al. found that 
elastin accounted for the same percentage of total stiffness regardless of pressure, while 
the majority of total stiffness is borne by parallel collagen at low pressures and almost 
overwhelmingly by VSM and series collagen at high pressures. Most strikingly, they 
measured a 15-fold increase in stiffness due to VSMC activity under isometric 
conditions, and that only 6% of total collagen fibers were recruited to bear wall stress at 
an average pressure of 100 mm Hg (Bank et al. 1996). Their designation of strong 
activation-induced increases in stiffness as due to recruitment of collagen may be 
consistent with my findings on focal adhesion regulation and encourages exploration of 
this model in the aorta. 
5.2.4 Model Applicability to Aortic Stiffness 
Bank’s modified Maxwell model of wall stress (Bank et al. 1996), consisting of a 
contractile element in series with collagen, warrants an evaluation of compatibility with 
my own findings, depicted in Figure 5.1 and quantified as: 
σ T = σ e + σ c(p) + σ SM-c(s)     Equation 5.1 
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Figure 5.1. Modified Maxwell model for total wall stress in the brachial artery 
(Bank et al. 1996). The passive parallel elastic component consists of extracellular 
matrix proteins: elastin and collagen. The active component consists of smooth muscle in 
series with additional collagen. Collagen behaves analogously to stiff springs that are 
progressively recruited as the vessel undergoes large strains (parallel) or as the smooth 
muscle contracts (series). The elastic behavior of the collagen fibers is proportional to the 
fraction of fibers recruited. 
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where the individual terms of the total T assigned to elastin e, parallel collagen c(p), and 
smooth muscle/collagen series SM-c(s) are quantifiable by isolating them under certain 
conditions. For example, the elastin component could be isolated from stiffness 
measurements at very low levels of strain, where elastin is known to dominate, and the 
inverse of this directive would apply in the case of collagen. While it is possible to 
interpret some of these values from my quasi-static stress-strain experiments, there is no 
way to compare these data to my database of VSM contributions to aortic stiffness 
derived from HFLA measurements. 
Therefore, more HFLA experiments would be necessary to maintain consistency 
and comparability in this regard. Additional parametric adjustments will likely be 
necessary to reconcile the expected discrepancies during the adaptation of this model, 
which should run parallel to implementation of improvements to the ex vivo stiffness 
protocol. 
 
5.3 Methodological Advantages in Reductionism and Physiological Relevance of 
High-Frequency Low-Amplitude Stiffness Measurements 
The traditional engineering approach of large-scale stress-strain analysis, 
prevalent in mechanical analysis of materials, typically uses a high-amplitude ramp input 
that produces a stress-strain curve through loading and unloading a tissue sample with 
large stretches from the unloaded state, otherwise known as slack length or 0% strain. 
Stiffness in this protocol is defined as the incremental slope (stress-strain ratio) at a 
particular strain level. In my aging study, I used stress-strain curves to contextualize my 
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observations of aortic stiffness with aging at specific strain levels (Chapter 3.4.5). At high 
strain levels, old aortas have higher passive material stiffness consistent with greater 
collagen content and recruitment (Wagenseil and Mecham 2012). On the other hand, I 
confirmed the lack of a stiffness increase in old aortas at physiologic strain levels, which 
I ascertained with the HFLA protocol. 
While stress-strain curves define a large pool of stiffness data across a wide range 
of strain values, the high-amplitude protocol used to collect these data has several 
disadvantages. The large stretches disrupt actomyosin cross bridges, decreasing 
contractile responses in the VSM and removing a major source of cellular stiffness. In 
addition, VSMC force output depends critically on the level of stretch it experiences 
(Peiper et al. 1974). Therefore, large-amplitude stretches disturb the system whose 
properties I am trying to measure. Furthermore, the stress-strain curve protocol stipulates 
the slack or unloaded state as the equilibration point before and after stretch; this 
prohibits the acquisition of steady-state stress data at any physiologically relevant aortic 
strain or during the response to a contractile agonist, factors more relevant to the in vivo 
environment of the aorta. 
In contrast, the HFLA protocol uses low-amplitude stretches and ample 
equilibration time after perturbations and treatments, in correspondence with traditional 
isometric studies of SMC contractility, cause minimal perturbation of the system 
(Brozovich and Morgan 1989, Kawai and Brandt 1980). Additionally, I am interested 
specifically in the mechanical properties of the aorta under physiologic conditions. HFLA 
allowed us in the present study to determine both steady-state stress and local stiffness 
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via incremental stress-strain measurements at optimal length that upholds SMC activity. 
Although intended to minimize perturbation of smooth muscle dynamics, HFLA 
stretch at 40 Hz with small positive offset does have noticeable effects as interpretable 
from the force response. Typically, there is a slight drop in the average force reading. 
This was seen before and after stimulation with PE but was much more pronounced post-
activation. Especially notable is the contractile response, which corrects itself upon 
cessation of the oscillatory stimulus. Figure 5.2 offers a sample depiction of these 
observations. It is possible that this initial drop reflects a pre-conditioning process of the 
tissue to uniaxial cyclic stretch described in previous studies as “stress softening” 
(Holzapfel et al. 2000). Stress softening may be compatible with the Barra-Armentano 
view that vascular smooth muscle cells are mechanically equivalent to “smart viscoelastic 
spring-dampers,” offering protective effects through remodeling in response to pulsatile 
pressures of blood flow, adjusting energy dissipation due to high-frequency vibrations 
that would otherwise induce wall damage (Armentano et al. 2007). This is essentially 
complementary to my proposed model of aortic shock absorption discussed in Chapter 
3.5.3. 
To assess whether the HFLA protocol successfully minimizes viscous damping in 
force response to stretch, I conducted simple phase lag analysis of individual force-length 
response traces as summarized in Figure 5.3. Chart software can resolve length, force, 
and time to the nearest 0.5 μm, 0.5 mg and 0.001 seconds respectively, and at these scale 
factors, there was no significant phase difference in peak-to-peak intervals between 
length input (dL) and force output (dF), even after smooth muscle activation by PE  
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Figure 5.2. HFLA stretch ex vivo induces stress softening and indicates possible 
protective effect from vascular smooth muscle. Typical force trace of response to 
HFLA stretch before and after agonist-induced contractility in young mouse aorta is 
shown. (1) At 40 Hz, sinusoidal oscillatory input with small positive offset produces 
slight damping in average force response near the beginning of stimulus duration. (2) 
Smooth muscle cells are activated with alpha agonist phenylephrine. (3) Stress softening 
is greater upon post-activation HFLA stretch. (4) Contractility is restored post-stretch. 
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Figure 5.3. HFLA stiffness measurements minimize viscoelastic response from 
aortic tissue. (A) Over the course of ~20 seconds, four oscillatory periods consistently 
occur within the same one-tenth of a second (red) for both length input (dL) and force 
output (dF), irrespective of stress softening (left) that results in an overall decrease in the 
average force measurement to steady-state (right). (B) Superimposition of length and 
force changes during four cycles of typical HFLA stretch normalized to their oscillatory 
peaks. The phase lag for these traces was 1.47 degrees. (C) Typical hysteresis for one 
oscillatory cycle during softening (solid-line)) and steady-state (dashed) phases. Energy 
dissipation (bounded area) between loading (red) and unloading (blue) curves: 2.99 nJ 
softening, 1.92 nJ steady-state. 
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resulted in a drop in the force reading, as visualized in Figure 5.3A. Normalizing time 
courses for dL and dF to their maximal values, as shown in Figure 5.3B, rendered them 
comparable to complex vectors, enabling usage of the dot product to calculate a very 
small phase angle between them. Finally, energy dissipation was calculable by directly 
plotting the loading and unloading curves in the force-length plane, as is seen in Figure 
5.3C, and determining the area inside the enclosure. In short, hysteresis was observable 
during stress softening, but was comparatively negligible at steady-state. 
The lack of a significant viscoelastic effect in the current protocol may signify 
closer emulation of in vivo conditions, consistent with previous studies that have found a 
three-fold decrease in viscosity for in vivo aorta relative to ex vivo samples, and that 
smooth muscle tone is likely not responsible for viscous effects observed ex vivo 
(Boutouyrie et al. 1998). A stronger interpretation may be that the fleeting damping effect 
observable during stress softening is due to recruitment of collagen by the VSMCs. 
These analytical results solidify the rationale for a transient HFLA stimulus. 
Superficially, it might seem far more appropriate to prescribe a level of stretch that is 
closer to that which is experienced during physiological blood flow, or what would 
essentially be a “physiologic stress-strain” protocol. One may easily intuit that a 
superimposed oscillatory input imposed upon optimal length should reflect the systolic 
pulse wave, and that the frequency and amplitude of the stimulus should correspond to 
typical heart rate and aortic distension experienced during systole, determined to be 8–10 
Hz and ~10% strain from previous in vivo C57BL/6J mouse studies (Doevendans et al. 
1998, Trachet et al. 2015). On the other hand, it may be presumptive to prioritize 
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parametric conditions over biological ones. I have already established critical differences 
between in vivo and ex vivo observations related to aortic stiffness in the context of 
smooth muscle viability. While I do not dismiss the basis behind a proposed physiologic 
stress-strain protocol, I believe that it may be more immediately valuable to seek minor 
corrective options while maintaining current parameters, rather than major changes to the 
overall methodological philosophy and a subsequent overhaul in experimental design. 
 
5.4 Motivating Factors for Future Improvements in Measurements of Ex Vivo 
Aortic Geometry 
Although the current method for ex vivo aortic stiffness measurements can 
satisfactorily maintain viable VSMCs, a number of minor but important changes could be 
made to the experimental apparatus to account for various geometric factors that would 
enhance the accuracy of subsequently collected data. 
 
5.4.1 Initial Length 
The measurement most prone to human error during the ex vivo aortic stiffness 
protocol is the resolution of the initial, or slack, length of a tissue sample. After mounting 
the tissue, initial length defined as the point beyond which any circumferential applied 
results in a positive change in the electronic force reading of the apparatus, which may 
not always be immediately detectable, given the inherent variability in readings due to the 
highly sensitive force transducer. Calibration of the equipment using this method is 
consistent, but also largely a heuristic process, refined with practice over hundreds of 
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independent experiments and supplemented with visual inspection of the mounted tissue. 
In theory, small adjustments of the lever arm, with the tissue initialized to an unloaded 
state, in order to determine slack length as close to the true value as possible, should have 
a minimal effect on the viability of the tissue. Also, despite the susceptibility to human 
error, this discrepancy is likely to be quite small in magnitude. Still, it may be desirable 
to develop a method enabling the determination of initial length more definitively. 
 
5.4.2 Axial Strain and Axial Shortening 
The experimental setup I used to produce ex vivo stiffness measurements imposed 
only uniaxial stretch in the circumferential direction in aortic samples. While this 
approach is fundamentally substantiated by the known circumferential orientation of the 
lamellar networks within the aortic wall (Holzapfel et al. 2000), it does not account for 
non-negligible axial stress and strain experienced by blood vessels in vivo due to normal 
biological organization and associated hemodynamics (Humphrey et al. 2009). There is 
no axial strain on the tissue sample in the current protocol, though it has been shown that 
physiologic axial strain is 10–20% in the proximal thoracic aorta (Doevendans et al. 
1998). One indirect consequence was that during stress-strain experiments as detailed in 
Chapter 3.4.5, visible shortening in the axial direction was observed beyond 250% strain. 
Aside from the increased tendency for tissue to rupture above this level of stretch, this 
was the major factor limiting the range of analysis to a maximum of 250% strain. 
Applying axial strain to the tissue in the current setup, possibly by fixing the ends 
of the tissue sample once it is mounted onto the triangular clasps, may prove 
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counterproductive to VSMC viability, extend experimental duration significantly, and 
increase the complexity of data interpretation. To maintain the current paradigm of 
reductionism, I propose that the issue of axial strain be revisited at a later iteration of this 
protocol, or evolve into a separate study. Alternatively, axial shortening could be 
measurable via high-resolution image analysis, even with the usage of a simple camera 
installation separate from the apparatus, though one would have to accommodate any 
refraction within the solution-filled organ bath. The most relevant consideration in this 
regard is whether or not any potential correction would differ with aging, as this has not 
been studied to my knowledge. 
 
5.4.3 Wall Thickness 
The thickness of the aortic wall will change upon stretching a tissue sample. 
Presently, there is no way to monitor thickness in real time after mounting the aorta on 
the apparatus. Instead, thickness is only ascertainable from separately imaging small 
rings cut from the ends of the segment to be stretched. Naturally, these small rings are not 
under physiologic strain and subsequent evaluation of thickness is not equivalent to that 
of the experimental sample under stretch. Again, this discrepancy could differ with aging, 
adding another variable to the final measurement that is not worrisome on its own, but 
contributes to cumulative geometric inaccuracy. Unfortunately, it is impossible to 
measure thickness of the stretched tissue without completely altering the current 
apparatus. The most appropriate remedy would be to address axial shortening, then apply 
a correction factor under the assumption that conservation of volume applies to the tissue. 
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5.4.4 Cross-Sectional Area and True Circumferential Strain 
In my analysis, I stipulated that uniaxial stretch equates to circumferential strain 
incurred by the tissue sample at the midpoint in the direction of stretch, where the 
geometry can be approximated as a rectangular prism, thus simplifying the relevant 
cross-sectional area A to A = 2hl, where h is the wall thickness and l is the axial length. 
While it may seem that this calculation of cross-sectional area—critical to normalizing 
force responses to stress and stiffness—is subject to the same discrepant factors relevant 
to axial shortening and wall thickness, there is an additional variable in the final 
determination of area: the triangular wire clasps. 
To obtain the stress-strain curves detailed in Chapter 3.4.5, it was necessary to use 
0.01-inch wire, which was twice the diameter of that which was used for physiologic 
strain stiffness experiments. This is equivalent to 254 µm. I have previously established 
in Chapter 3.4.2 that average unloaded wall thickness of a young mouse aorta is under 60 
µm, while average lumen diameter is 641 µm. Therefore, this thicker triangular wire has 
a non-negligible diameter that is greater than one-third the lumen size. Even the thinner 
0.005-inch wire has a diameter greater than twice the wall thickness of a young aorta. 
As a result, when we examine the actual geometric configuration of a stretched 
aorta, it resembles the schematic shown in Figure 5.4. These considerations give rise to a 
correction factor for true circumferential strain εactual, taken as the ratio between the actual 
stretched circumference, Cactual, calculated as shown in Equation 5.2, and its unloaded 
value at rest, which is simply π multiplied by the measured unloaded outer diameter d. 
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Figure 5.4. Deriving a correction factor for true circumferential strain in uniaxial 
stretch of aortic tissue. Schematic cross-sectional view of two wires of diameter w, an 
aortic ring segment with measured unloaded outer diameter d and wall thickness h, and 
the visual approximation of using the two wires to stretch the tissue uniaxially to desired 
length L, defined here as 1.8 times d. With the assumption that the most accurate 
definition of L, corresponding to the movement of the lever arm in the HFLA apparatus, 
is the distance between the centers of the wires, the actual circumference can be 
calculated as 2 L (the sections parallel to the direction of stretch) + π (w + 2 h2) (the 
sections wrapped around the wires). 
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Cactual = 2 L + π (w + 2 h2)     Equation 5.2a 
εactual = Cactual / πd      Equation 5.2b 
 
Thus, I can determine the actual outer circumference of the wall for a desired 
strain level L (in this case 80% strain, or 1.8 times the resting outer diameter as depicted 
in Figure 5.4), the size of the wire w, and the altered wall thickness h2, which we can 
correct by applying conservation of volume to observed axial shortening to obtain a 
quadratic equation for h2 with coefficients a, b, and c in terms of unloaded vessel outer 
diameter d, unloaded thickness h1, unloaded axial length l1, and shortened axial length l2: 
a = 1, b = -d, and c = l1/l2 (h12 – dh1). Through this method, I could calculate h2 after 
measuring l2 to ascertain more precise values for cross-sectional area and true 
circumferential strain. 
The ability to use this correction factor to its fullest extent is limited, as I have 
previously established that the experimental setup does not accommodate procedural 
measurements of axial shortening and thickness changes. Furthermore, it follows that the 
tissue may not truly be experiencing physiologic optimal length, and that, given the range 
of maximal contractility established in Chapter 3.4.1, I could implement strain correction 
in order to determine more accurately the amount of stretch required to reach 80% strain. 
Unfortunately, adding this step would require unloaded thickness measurements before 
the initial stretch, as well as real-time determination of axial shortening. Currently, the 
former is impractical as it would lengthen the experiment significantly, which is 
problematic for sustained viability of freshly dissected aortic samples if they are not 
immediately used, while the latter is not possible. If attempts to resolve these issues 
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methodologically are unsuccessful or impractical, a heuristic estimate for the average 
shortening and thickness changes experienced by samples of specific age and geometry 
may be an appropriate compromise in this regard. 
Finally, it is prudent to return briefly to the discussion of wire size used for 
uniaxial stretch. Wire diameter is already incorporated into the equation for area and 
strain correction factors, so it is more important to consider the biological implications, 
rather than the mathematical ones, of using a certain wire size over another. It is much 
easier to mount the tissue with smaller wires, which occupy less of the lumen. This 
reduces the chance that the wires will cross and necessitate correction; repeated 
adjustments are likely to subject the tissue to unmeasurable and possibly harmful pre-
stretch, leading to damage in SMCs and especially the endothelium, the latter of which 
can drastically affect stiffness measurements post-VSMC-activation, as I have previously 
detailed when discussing the inhibition of NOS. On the other hand, larger wires are 
effectively mandatory when applying extremely high-amplitude stretches to the tissue. In 
addition to axial shortening, visible deformation of the smaller wires corresponded to 
stretches beyond 250% strain during initial test experiments in pursuit of the stress-strain 
curve data presented in Chapter 3.4.5. Larger wires would mostly counter the risk that 
deformation might occur even at lower strains, albeit microscopically. Based upon these 
considerations, I believe that it is correct to default to smaller wires in order to uphold 
viable VSM. 
Here, the progressive evaluation of every aspect of my methods to measure aortic 
stiffness ex vivo has reinforced many design choices I made, but also acknowledges 
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various shortcomings that should be addressed in order to improve the quality of these 
procedures. Nevertheless, the novelty of the knowledge presented in this dissertation 
owes to the research interests of me and our group to focus on the role that vascular 
smooth muscle plays in aortic stiffness. Efforts to amend protocol should retain thematic 
constancy and optimize the assessment of parameters without sacrificing any features that 
are currently integral to the preservation of smooth muscle viability. 
 
5.5 Interpretation of Ex Vivo Results for In Vivo Predictions 
Despite limiting characteristics of an ex vivo environment, I attempted to mimic in 
vivo conditions as closely as possible in my aging study. At physiologic mean strain and 
optimal length, in oxygenated salt solutions containing extracellular calcium, maintaining 
body temperature, and with fully viable VSMCs, I measured in this study material 
stiffness of young and old mouse aorta with high reproducibility. 
The ex vivo measurements of aortic mechanical properties presented in this 
dissertation motivate the reconsideration of what “stiffness” means in a clinical 
(functional) context versus a scientific (material) one. On the clinical side, pulse wave 
velocity has great epidemiological value, but the extent to which it is truly a direct 
correlate of aortic stiffness is unclear, especially when interpreting observed increases 
with aging. Meanwhile, direct stiffness measurements from tissue samples enable the 
most reductive evaluation of biomechanical properties, but do not account for variable 
environmental conditions in vivo. According to the Moens-Korteweg equation, PWV is 
proportional to the square root of stiffness, but the actual relationship between these two 
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values is far less straightforward. The question arises as to how one might bridge the gap 
between the utility of PWV as a prognosticator and the robustness of ex vivo material 
stiffness as a biomechanical standard. 
In this section, I briefly discuss a non-exhaustive list of several investigative 
possibilities to address this issue, stemming from discussion points presented throughout 
this dissertation. 
 
 Animal models. The research presented in this dissertation was almost entirely 
performed in mice. As noted in Chapter 2.3, mice are not as physiologically 
comparable to humans as other animal models, such as ferret. 
 Wall thickness and vessel diameter. As noted in Chapter 3.4.2, both wall thickness 
and outer diameter increased with aging in mouse aorta. These parameters are both 
relevant in the Moens-Korteweg relation. Thickness increased ~35% with aging, 
while outer diameter increased ~24%. This results in an expected increase of only 
~4% in PWV, so these geometric considerations are insufficient. I have previously 
mentioned the difficulties in measuring changes in geometry during ex vivo stiffness 
experiments, but there are also challenges in vivo, as mice are generally anesthetized 
for PWV measurements, thus limiting the equivalence to true in vivo conditions 
during normal physiological activity. 
 Axial strain. The current protocol applies only circumferential strain and does not 
account for the axial strain experienced by aorta in vivo (Humphrey et al. 2009). 
Accommodating axial stiffness is beyond the scope of this dissertation, but axial 
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strain may also raise basic geometric considerations for potential differences with 
aging in axial length that factor into the calculation of cross-sectional area. 
 Operating strain. An operating strain of 80%, evaluated in Chapter 3.4.1 and 
approximate of the strain experienced in vivo during normal blood flow, was applied 
in both young and old mouse aortas. This enabled optimally comparable values of 
material stiffness, but to the best of my knowledge, in old mice there is no definitive 
physiologic strain range. Therefore, differences with aging in functional stiffness 
could well be attributable to non-identical operating strains. 
 Physiologic stress-strain perturbations. HFLA stretch is designed to minimize 
perturbations to cross bridges, but in vivo aortas undergo significantly larger 
deformation during the cardiac cycle, which may in itself alter cross bridge formation. 
One can alter the parameters of sinusoidal oscillations to match expected frequency 
and amplitude, corresponding to heart rate and systolic circumferential distension 
experienced in vivo, as previously discussed at the end of Chapter 5.3. 
 Viscoelasticity. While HFLA stretch, coupled with smooth muscle activation, does 
minimize viscoelasticity in aortic stiffness measurements, a more physiologic stretch 
protocol at lower frequencies and higher amplitudes would almost certainly give rise 
to more pronounced viscosity in the response of the aortic wall. Additionally, any 
discrepancy in parameters that characterize an accurate “physiologic” stimulus for 
young versus old aortas would further highlight a difference in their respective 
viscoelastic properties. Results from previous in vivo arterial studies in dogs (Gamero 
et al. 2001) and sheep (Gamero et al. 2002), including those shown in Figure 5.5,  
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Figure 5.5. Frequency dependence of the magnitude of normalized dynamic elastic 
modulus during control and active (Phen) states in dogs (Gamero et al. 2001). Mean 
values cited from past studies (Others) are also shown. 
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have shown interdependence between factors such as smooth muscle activation, heart 
rate or stimulus frequency, and vessel diameter—all previously discussed in this 
work—in measurements of viscoelasticity. Although these relations may not hold 
exactly in the context of mouse aorta or even in humans, they provide strong evidence 
that there are multiple variables that could all contribute cumulatively to differences 
in vessel stiffness with aging. 
 In vivo regulators of smooth muscle activation. Following these points, another 
element missing from an ex vivo environment is the presence of multiple ill-defined 
neuro-humoral mediators, the absence of which would mainly affect the smooth 
muscle cells (Armentano et al. 2007). A comprehensive database of these mediators is 
lacking and the manner in which they might adjust smooth muscle activation levels is 
currently not well-known. The ex vivo results in this dissertation, specifically through 
usage of phenylephrine and L-NAME, define the maximal activation states in aortic 
smooth muscle and quantify them as components of total stiffness. Therefore, the 
details of in vivo activation states, and whether they differ with aging, are left to 
future studies. 
 Endothelial response to shear stress. It is appropriate and necessary to understand the 
aging of the endothelium in concert with that of aortic smooth muscle. Nitric oxide is 
a critical regulator of vascular smooth muscle contributions to aortic stiffness. Here I 
have shown the capacity of NO to dramatically modify the biomechanical properties 
of the aorta. Levels of NO activity have especially wide-reaching implications in the 
context of shear stress, which is experienced in vivo but not taken into account in my 
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ex vivo experiments. In fact, the endothelium produces NO to alleviate shear stress 
resulting from blood flow in a Src-dependent manner, transiently by increasing 
transcription for nitric oxide synthase, which leads to long-term stability of 
endothelial NOS (Davis et al. 2001). Unfortunately, determination of NO released at 
any point in time in vivo by blood shear forces is technically challenging (Irace et al. 
2012, Soucy et al. 2006), but this connection to my finding in Chapter 3.4.9 that Src 
availability decreases with aging hints at the critical and possibly aging-deficient role 
that Src might play in reducing aortic stiffness through the endothelium. 
 
The results of the aging study detailed in Chapter 3 are an important first step in 
fully understanding the mechanisms of changes in aortic stiffness with aging, with a 
spotlight cast on Src-dependent regulation in vascular smooth muscle. In Chapter 4, 
potential molecular targets for the prevention or reversal of aging-induced aortic stiffness 
were probed. This chapter began with my proposal for integration of aortic stiffness data 
obtained here with existing quantitative models based upon previous literature. Then, I 
conducted a more detailed methodological review of how these data might be acquired 
more robustly moving forward. Finally, I outlined the current uncertainties in using ex 
vivo aortic stiffness to frame the understanding of its in vivo representations, most 
significantly in the form of pulse wave velocity, in encouragement of future elaboration 
upon the body of work featured in this dissertation. 
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Chapter 6: Conclusions 
 
To this point in modern biomedical research, the notion of smooth muscle as the 
likely lynchpin for structural and functional integrity within blood vessels and its 
translation into scientific strategy have not been adequately appreciated. Although this 
work has attempted to confer convincing evidence for aortic smooth muscle cells as 
important sites of biochemical and biomechanical regulation, it is still limited in scope 
and serves sufficiently only as an underpinning for future inquiries, both rational and 
empirical. 
Overarching principles of hemodynamics have supported the assertion that 
increased pulse wave velocity with aging incident and observable in vivo reflects higher 
aortic stiffness, an outcome interpretable in and correlative to cardiovascular pathologies. 
Therefore, aortic stiffness has emerged within the clinical repertoire as a vitally important 
prognosticative tool for cardiovascular disease. It is desirable to seek a greater 
understanding of the biological processes that manifest and explain this relationship, thus 
strengthening the biomechanical basis of this diagnostic method and motivating the 
conception and development of possible therapeutic treatments. 
Most mechanical studies of the vasculature have emphasized the extracellular 
matrix proteins elastin and collagen and put forth the conjecture that these are the primary 
constituents of aortic material stiffness. Such an emphasis on these extracellular 
components of the aortic wall may be attributable to the relative ease with which one may 
study them ex vivo. In contrast, this dissertation offers new and novel insights into 
111 
biological principles underlying the quantification of significant contributions from 
smooth muscle cells in the regulation of total aortic stiffness, especially in the context of 
aging-induced dysfunction in relevant cellular mechanisms. Ex vivo stiffness 
measurements were demonstrated to be separable into distinct quantities corresponding to 
specific components of the aortic wall. This led to the definition of active stiffness, the 
proportion of total stiffness that is discernible only upon activation of aortic smooth 
muscle cells. Under physiologic conditions, the active component constitutes roughly half 
of maximal total stiffness. Defective smooth muscle regulation of stiffness, specifically 
with respect to signaling pathways characterizing protective and compensatory 
mechanisms within focal adhesions and the non-muscle cytoskeleton tied to the 
regulatory kinase Src, accounts for aging-induced increases in stiffness. 
These findings may spur efficient, specific, and safe therapeutics to treat 
increased aortic stiffness. Preliminary studies presented here used prototype drugs, in the 
form of cell-permeable peptides, to probe potential cellular targets. Successful inhibition 
of active stiffness in young aortas was achieved by peptides directed to compete with two 
specific protein-protein interactions regulating focal adhesion dynamics and actin 
polymerization. Moreover, aging-induced increases in active stiffness were tempered by 
targeting a specific interface between talin and vinculin that plays an important structural 
role in focal adhesions. Despite these promising beginnings, much remains to be done en 
route to developing a viable option for the treatment of aging-induced aortic stiffness. 
Further studies are required to expand or establish more concretely a catalog of potential 
therapeutic targets and also to address important pharmacological considerations of drug 
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efficacy, potency, specificity, and delivery. 
The distinct procedures employed to acquire the quantitative results presented 
here warranted a critical methodological review in anticipation of future studies. This 
analysis concluded that there is a strong potential compatibility between these findings 
and existing mathematical models in other arteries that propose a significant role for 
vascular smooth muscle in the determination of vessel stiffness. Suggested improvements 
to the experimental design would serve only to enhance the precision of ex vivo stiffness 
measurements. These would serve to develop more a robust representation of aortic 
biomechanics and strengthen the link between clinical assessment and scientific 
knowledge. 
Biomedical engineering is a discipline that aspires to combine strong biological 
evidence with sound engineering principles in order to devise new technologies and 
medicines to improve human health. It is the hope of the author that this offered work has 
adhered faithfully to this philosophy and contributed, however incrementally, toward 
overall progress in confronting the clinical challenges of cardiovascular disease. 
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